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INTRODUCTION 
Analytical chemistry is a branch of chemistry that deals with the separation, 
identification and determination of components in a sample. It is the science of 
making quantitative measurements, which requires background knowledge of 
chemical and physical concepts.  
Analytical chemistry may be defined as the science and art of determining the 
composition of material in terms of elements or compounds contained in it.  
For analysis of these drugs different analytical methods are routinely being used. 
These analytical methods are classified as classical and instrumental.  
•  The classical methods include Gravimetric and Titrimetric. 
    These methods are simple but less precise and more time consuming so 
    Now a days these methods are not suggested for the routine analysis.  
• The instrumental methods include electrical methods -voltametry, 
Coulometry and optical methods - absorption and emission methods. 
• The absorption methods include visible spectrophotometry, ultraviolet 
spectrophotometry, infrared spectrophotometry, atomic absorption 
spectrophotometry and emission methods include emission spectroscopy, 
flame photometry, fluorimetry, etc.  
• The other prominent methods include isotopes, radioactivity, x-ray 
fluorescence and separation methods as various chromatographic principles 
viz. HPLC, GC and HPTLC etc. 
These methods like HPLC, Spectrophotometry are easy to perform, precise 
and show reproducible results as compared to any other methods 
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Importance of Analytical Methods 
The newly developed analytical methods having their importance in different 
fields 
• Research & Development Centre 
• Quality control Department  
• Approved Testing Laboratories 
• Chemical Analysis Laboratories 
Principle of chromatography 
Different affinity of the different components to stationary phase causes the 
separation. They are then flushed through the system at different rates. These 
differential rates of migration as the mixture moves over adsorptive materials 
provide separation. Repeated sorption/ desorption acts that take place during 
the movement of the sample over the stationary bed determine the rates. The 
smaller the affinity a molecule has for the stationary phase, the shorter the 
time spent in a column. 
 Chromatography Techniques 
Classification of Chromatography Techniques 
   I]    According to the nature of stationary and mobile phase 
• Gas Solid Chromatography 
• Gas Liquid Chromatography 
• Solid Liquid Chromatography 
• Liquid Liquid Chromatography 
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 II] According to mechanisms of separation, chromatographic methods are divided 
into    following general area 
• Adsorption chromatography 
• Partition chromatography 
• Size exclusion chromatography 
• Ion exchange chromatography        
            Adsorption chromatography, the analytes interact with solid stationary 
surface and are displaced with the eluent for active sites on surface. 
             Partition chromatography, results from a thermodynamic distribution 
between two liquid (or liquid like) phase. On the basis of relative polarities of 
stationary and mobile phases. Partition chromatography can be divided into normal 
phase and reverse- phase chromatography 
               Size-exclusion Chromatography, involves a solid stationary phase with 
controlled pore size. Solutes are separated according to molecular size, with the large 
molecules unable to enter the pores elute first. 
              Ion-exchange Chromatography, involves a solid stationary phase with 
anionic or cationic groups on the surface to which solute molecules of opposite 
charges are attracted. 
               In chromatographic separation, HPLC and HPTLC methods have widely 
been exploited in pharmaceutical analysis because of its simplicity, precision, 
accuracy and reproducibility of results. 
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High Performance Liquid Chromatography  
High performance liquid chromatography is basically a highly improved form 
of column chromatography. Instead of a solvent being allowed to drip through a 
column under gravity, it is forced through under high pressures of up to 400 
atmospheres. That makes it much faster. 
It also allows you to use a very much smaller particle size for the column 
packing material which gives a much greater surface area for interactions between the 
stationary phase and the molecules flowing past it. This allows a much better 
separation of the components of the mixture. 
The switch to the use of small particles requires much higher pressure 
instruments to pump mobile phase through a column. The later developed technique 
i.e., Ultra-high pressure liquid chromatography (UHPLC) uses the sub 2 µm particles 
which results  in the system pressure exceeding 6,000 psi pressure limit, all the way 
up to 19,000 psi. However the introduction of fused core silica particles of sub 3 µm 
reduced the system pressure and with increased efficiency. 
 
Instrumentation 
Figure 1: Schematic representation of HPLC instrumentation 
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 HPLC instruments consist of a reservoir of mobile phases, pumps, an injector, a 
separation column, a detector and a data control and processor. Solvents must be  
degassed to eliminate formation of bubbles. The pumps are provided with pulse 
dampers, so that to attain a steady high pressure with pulse free flow and can be 
programmed to vary the composition of the solvent during the course of the 
separation and deliver the desired flow and composition of the mobile phase through 
the column.. The liquid sample is introduced into a sample loop of an injector with a 
syringe or an auto-sampler. The presence of analytes in the column effluent is 
detected by detectors and amplified into a signal by data processor. The various types 
of detectors used in HPLC are UV/visible detectors, refractive index detector, 
fluorescence detector, electrochemical detector, conductivity detector, light scattering 
detector. Spectrometric detectors are used in hyphenated HPLC methods such as 
LC/MS, LC/NMR, and LC/GC etc. 
Modes of Separation in Liquid chromatography 
Normal-Phase Chromatography 
Normal-phase chromatography, or NP, is the classic form of liquid 
chromatography using polar stationary phases and non-polar mobile phases. The 
analyte is retained by the interaction of its polar functional groups with the polar 
groups on the surface of the packing. Analytes elute from the column starting with the 
least polar compound followed by other compounds in order of their increasing 
polarity. Normal-phase chromatography is useful in the separation of analytes with 
low to intermediate polarity and high solubility in low-polarity solvents. Water-
soluble analytes are usually not good candidates for normal-phase chromatography. 
Reversed-Phase Chromatography 
Reversed-phase chromatography, or RP, has become the most common mode 
of liquid chromatographic separation. In RP the stationary phase is non-polar and the 
mobile phase is polar. The analytes are attracted to the surface by their non-polar 
functional groups. The most polar analyte elutes from the RP column first followed by 
other analytes in order of decreasing polarity. RP chromatography is useful for the 
separation of compounds having high to intermediate polarity. 
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Ion-Exchange Chromatography 
Ion-exchange chromatography separates analytes by their ionic functionality. 
Ion-exchange stationary phases are usually comprised of ionic species attached to the 
surface of the silica substrate or ionic functional groups evenly distributed throughout 
a polymeric media. Weak ion-exchange phases are usually pH dependent. Strong ion-
exchange phases are always charged and therefore independent of typical pH changes. 
Ion-exchange columns with low capacity are used for ion chromatographic 
applications where low ionic strength mobile phases are required for conductivity 
detection. 
Gel permeation chromatography 
Gel filtration or gel permeation is a process by which molecules can be 
separated according to their size (molecular weight) and sometimes shape. Small 
molecules get trapped and slowed down in the pores of the beads but large molecules 
simply flow down the column. Therefore larger molecules come out first. 
Affinity Chromatography 
Affinity chromatography is based on specific interactions in a lock-and-key 
paradigm between analytes and matrix-bound ligands. Dependent on the secondary 
structures of biological macromolecules for retention of selected sample components, 
affinity chromatography is without question the most highly specific, and 
consequently the most powerful, mode of chromatography. 
Chiral chromatography 
Chiral chromatography is a chromatographic technique in which the stationary 
phase contains a single enantiomer of a chiral compound rather than being achiral. 
The two enantiomers of the same analyte compound differ in affinity to the single-
enantiomer stationary phase and therefore they exit the column at different times. 
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The role of HPLC in drug analysis 
 
a) Discovery 
 
• High throughput  screening and bio analysis 
 
b) Development 
 
• Method development and validation 
 
 
c) Manufacturing 
 
• Dissolution  
• Content Uniformity 
• Assay 
• Drug impurities and stability 
• Inprocess and cleaning verification 
 
Applications of HPLC 
 
Separation and analysis of non-volatile or thermally-unstable compounds; 
• HPLC is optimum for the separation of chemical and biological compounds 
that are non-volatile. 
 
Qualitative Analysis: 
            The identification (ID) of individual compounds in the sample. 
• The most common parameter for compound ID is its retention time (the time it 
takes for that specific compound to elute from the column after injection). 
• Depending on the detector used, compound ID is also based on the chemical 
structure, molecular weight or some other molecular parameter. 
 
Quantitative Analysis: 
            The measurement of the amount of a compound in a sample (concentration)  
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Two main ways to interpret a chromatogram (i.e. perform quantification). 
• Determination of the peak height of a chromatographic peak as measured from 
the baseline. 
• Determination of the peak area. 
In order to make a quantitative assessment of the compound, a sample with a 
known amount of the compound of interest is injected and its peak height or peak area 
is measured. In many cases, there is a linear relationship between the height or area 
and the amount of sample. 
 
Preparation of Pure Compound(s): 
By collecting the chromatographic peaks at the exit of the detector, - and 
concentrating the compound (analyte) by removing/evaporating the solvent, - a pure 
substance can be prepared for later use (e.g. organic synthesis, clinical studies, 
toxicology studies, etc.). This methodology is called preparative chromatography. 
 
Trace analysis: 
 
A trace compound is a compound that is of interest to the analyst but its concentration 
is very low, usually less than 1% by weight, often parts per million (ppm) or lower. 
• The determination of trace compounds is very important in pharmaceutical, 
biological, toxicology, and environmental studies since even a trace substance 
can be harmful or poisonous. 
• In a chromatogram trace substances can be difficult to separate or detect. 
• High resolution separations and very sensitive detectors are required. 
 
 
Key variables in HPLC  
Column and its parameters: 
 Substrate  
Most separations are based on partition mechanisms using chemically 
modified silica as the stationary phase. The nature of the bonded phase is an important 
parameter for determining the separation properties of the chromatographic system. 
                                                                                                                                           Introduction 
Department of Pharmaceutical Analysis 9
 The surface of the support, e.g. the silanol groups of silica, is reacted with 
various silane reagents to produce covalently bonded silyl derivatives covering a 
varying number of active sites on the surface of the support. Silica-based columns are 
often used for separations of low molecular weight analytes using mobile phase 
solvents with a pH range between 2 to 8. Columns containing particles of polymeric 
materials such as styrene-divinylbenzene copolymer are stable over a wider pH range. 
Normal-phase HPLC uses unmodified silica, porous graphite or polar 
chemically-modified silica (e.g. cyanopropyl or diol) as the stationary phase while 
Reverse-phase HPLC uses mostly modified silica such as octadecyl silane, octyl 
silane,butyl silane etc.  
In case of reversed phase, the extent of bonding of the stationary phase is 
expressed as the carbon-loading. Furthermore, stationary phases may be "end-
capped", i.e. the number of residual silanol groups is reduced by methylation. These 
parameters contribute to the chromatographic behaviour of a particular stationary 
phase. Tailing of peaks, particularly for basic substances, can occur when residual 
silanol groups are present. 
Silica based columns are claimed to be ideal support for HPLC methods since 
they offers the following features: 
• Large mechanical stability 
• Excellent physico-chemical properties 
• A wide range of bonding chemistries 
• Compatible with a broad range of organic solvents 
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Table 1:
 Various types of columns and their applications  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Particle shape 
The first available HPLC columns were packed using irregularly shaped silica 
particles. Because of this, many standard analytical methods are still based on these 
materials. Irregular particles are also used in large- scale preparative applications 
because of their high surface area, capacity and low cost. 
The majority of new HPLC methods are performed on spherical shaped or 
spheroidal (almost spherical) particles. Spherical particles provide higher efficiency, 
better column stability and lower back-pressures compared to irregularly shaped 
particles. 
COLUMN PHASE APPLICATION 
C18 Octadecyl 
General 
Nonpolar 
Compounds 
C8 Octyl 
General 
Nonpolar 
Compounds 
PHENYL Styryl 
Fatty acids, 
Aromatic double 
bonded 
compounds 
CYANO Cyanopropyl Ketones, Aldehydes 
AMINO Aminopropyl Sugars, Anions 
DIOL Dihydroxyhexyl Protiens 
SAX Aromatic quarternary amine Anions 
SCX Aromatic 
sulphonic acid Cations 
DEAE Diethylaminoethyl Proteins, Anions 
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 Particle Size 
Particle size for HPLC column packing’s refers to the average diameter of the  
packing particles. Most HPLC packing’s contain a narrow range of particle diameters. 
Particle size affects the back-pressure of the column and the separation efficiency. 
Column back-pressure and column efficiency are inversely proportional to the square 
of the particle diameter. This means that as the particle size decreases, the column 
back-pressure and efficiency increase. A well packed column with sub 3 µm 
packing’s produces almost twice the separation efficiency of a comparable 5 µm 
column. However, this sub 3 µm column will have about a three-fold higher back-
pressure compared to the 5 µm column when operated with the same mobile phase 
and at the same flow rate.  But the newly evolved fused core silica particles( 2.7 µm)  
results in the reduced back pressures while staying within the range of 400 bar 
pressure limits of most of the HPLC instruments. Highly efficient, small-particle 
columns are ideal for complex mixtures with similar components.  
Larger particle (5 µm and 7 µm) columns are typically used for routine 
analyses where analytes have greater structural differences. Large 10 µm packing’s 
have only moderate column efficiencies. Columns packed with 10 µm packing’s are 
generally used as scout columns for future preparative separations, semi- preparative 
applications, or routine QA/QC methods where high chromatographic efficiencies are 
not required. Large particles (15- 20 µm) are used for preparative-scale separations. 
 Pore Size 
The pore size of a packing material represents the average size of the pores 
within each particle. The size of the analyte should be considered when choosing the 
appropriate pore size for the packing material. The molecular weight of an analyte can 
be used to estimate the size of the molecule. As a general rule, a pore size of 100 Å or 
less should be used for analytes below 3,000 MW. A pore size of 100 Å -130 Å is 
recommended for samples in the range of 3,000 MW - 10,000 MW. For samples 
above10,000 MW, including peptides and proteins, a 300 Å material provides the best 
efficiency and peak shape. 
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 Pore Volume 
Pore volume is a measurement of the empty space within a particle. Pore  
volume is a good indicator of the mechanical strength of a packing. Particles with 
large pore volumes are typically weaker than particles with small pore volumes. Pore 
volumes of 1.0 mL/g or less are recommended for most HPLC separations. Pore 
volumes of greater than 1.0mL/g are preferred for size-exclusion chromatography and 
useful for low-pressure methods. 
 Surface Area 
The physical structure of the particle substrate determines the surface area of 
the packing material. Surface area is determined by pore size. Pore size and surface 
area are inversely related. A packing material with a small pore size will have a large 
surface area, and vice versa. High surface area materials offer greater capacity and 
longer analyte retention times. Low surface area packing’s offer faster equilibration 
time and are often used for large molecular weight molecules. 
 Carbon Load 
The carbon load is a measure of the amount of bonded phase bound to the 
surface of the packing. High carbon loads provide greater column capacities and 
resolution. Low carbon loads produce less retentive packing’s and faster analysis 
times. 
 Surface Coverage 
Surface coverage is calculated from the carbon load and surface area of a 
packing material. Surface coverage affects the retention, selectivity and stability of 
bonded phases. 
 End-Capping 
A reversed-phase HPLC column that is end-capped has gone through a 
secondary bonding step to cover unreacted silanols on the silica surface. End-capped 
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packing materials eliminate unpredictable secondary interactions. Basic analytes tend 
to produce asymmetric tailed peaks on non-end-capped columns, requiring the 
addition of modifiers to the mobile phase. Non end-capped materials exhibit different 
selectivity from that of end-capped columns. This selectivity difference can enhance 
separations of polar analytes by controlling the secondary silanol interactions 
 Column Length, Diameter and Volume 
Always we should select the shortest column length that will provide the 
required resolution for the application. Once a packing material has been selected, the 
physical dimensions of the HPLC column hardware should also be optimized for the 
desired separation.It is important to understand the relationship between column 
length, diameter and volume. The column length (L) and internal diameter (d) 
determine the bed volume (V) of an HPLC column by the   following equation: V = L 
x πd2/4. This equation does not account for the reduction in liquid volume due to the 
packing material. It is an upper limit on the column volume – the minimum volume of 
mobile phase required to elute an unretained analyte from the column. Small column 
diameters provide higher sensitivity than larger column diameters for the same 
injected mass because the concentration of the analyte in the mobile phase is greater. 
Smaller diameter columns also use less mobile phase per analysis because a slower 
flow rate is required to achieve the same linear velocity through the column. HPLC 
instrumentation may need to be modified for columns with very small internal 
diameters to eliminate band broadening due to extra-column effects, i.e., mixing 
volumes outside the column. Longer columns often provide increased resolution. 
Larger-diameter columns provide greater sample loading and lower back-pressure. 
Column back-pressure for a given flow rate increases as the column length increases 
and as internal diameter decreases.  Fast, high-resolution separations can be achieved 
with small particles packed in short columns. 
 Column Flow Rate 
When the column dimensions are changed to optimize a separation or to scale 
a separation to a preparative or narrow-bore application, the mobile phase flow rate 
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should be adjusted proportionally to cross-sectional area of the column to maintain 
consistent linear velocity and retention times.  
It is not difficult to imagine that system pressure is affected by flow rate.  Flow rate 
impacts HPLC system pressure, chromatogram quality, and analysis time.  One must 
choose a flow rate that is appropriate for the HPLC system and column.  
A lower than usual flow rate may leave the analyst waiting for the peak to appear at 
the detector. A higher than usual flow rate may adversely affect the quality of the 
chromatogram not giving the analyte sufficient time to interact with the stationary 
phase. And this affect is more in case of smaller particles. However the fused core 
silica particles providing the shorter diffusional mass transfer path for solutes are less 
affected in resolving power by increasing flow rate than the sub 2 µm. 
 The plate height is related to the flow rate of the mobile phase, so for a fixed set of 
mobile phase, stationary phase, and analytes. Separation efficiency can be maximized 
by optimizing the flow rate. 
 Column temperature 
Temperature Control in HPLC is needed to attain reproducibility. Retention in 
HPLC is temperature-dependent. If temperature varies, then it is difficult to assign 
“peaks” to specific compounds in the chromatogram and the peak areas/heights may 
vary. 
Certain chemical compounds may relatively have low solubility in the HPLC 
mobile phase and if they are injected into the flow stream at more temperature they 
may precipitate or other difficulties may arise. 
Certain chemical compounds, especially biological compounds such as 
enzymes or proteins, may not be stable at room temperature or higher temperature. 
For such compounds the temperature needs to be much lower down to at about 4°C. 
System pressure is affected by temperature.  The viscosity of the mobile phase 
will decrease with increasing temperature.  For example if the HPLC system pressure 
is too high for a given solvent system the chromatographer may choose to raise the 
temperature of the column compartment to 40°C or even 60°C.  In terms of trouble 
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shooting high system pressure, adjusting temperature is not usually the first factor to 
consider.   
 Injection Volume:  
The injection volume should be very small and should be in the range of 
microliters for analytical scale HPLC methods. Typical sample volumes are 5-to 20-
microliters (µL). 
The injection volume is based on the length and internal diameter of the 
column. The injector must also be able to withstand the high pressures of the liquid 
system. Injection volume can also effect the peak width. 
 
 Mobile phase 
           The choice of mobile phase is based on the desired retention behavior and the 
physicochemical properties of the analyte. 
Proper selection of the mobile phase is the most important step in the 
development of the separation method next to selection of the adsorbent type. The 
main requirement for the mobile phase is that it has to dissolve the analytes up to the 
concentration suitable for the detection.  
The mobile phase in reversed-phase chromatography should be polar. 
Variation of the eluent composition provides the great flexibility of HPLC 
separations. Mostly a mixture of aqueous buffer and organic solvents are used as 
mobile phase in RP-HPLC. 
Table 2: Important parameters of some common solvents often used as eluent 
components in RP-HPLC 
Name MW BP R.I. UV[nm] Viscos.[cP] 
Acetonitrile 41 82 1.341 195 .358 
Methanol 32 65 1.326 205 .584 
Isopropanol 60 82 1.375 205 2.39 
Tetrahydrofuran 72 66 1.404 215 2.20 
Water 18 100 1.333 185 1.00 
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 pH and Buffer:  
             The pH of mobile phase can affect chromatography in a number of ways. 
Depending on the compound being analysed, pH can impact selectivity, peak shape 
and retention. 
                In RP-HPLC, pH and ionic strength of the aqueous portion of mobile phases 
are important in developing rugged methods not sensitive to small variations in 
conditions. With ionic compounds, retention of typical species shows significant 
changes with pH .It is very important to control pH in RP systems to stabilize 
retention and selectivity. A pH between 2 and 4 generally provides the most stable 
conditions for retention verses small changes in pH, and this pH range is 
recommended for starting method development with most samples, including basic 
compounds and typical weak acids. For reproducibility, the pH used should be plus or 
minus one pH unit above or below the pKa or pKb of the solute being separated. 
           Most RP silica-based columns work well from pH 2 to pH 8(i.e., most 
separations will take place between pH 2 and 8), providing a wide range when 
searching for the optimum mobile phase pH for a separation. Polymer-based HPLC 
columns have outstanding chemical stability and can be used from pH 1 to pH 14.  
           Method development proceeds by investigating chromatographic separations at 
low pH, and then higher pH, until optimum results are achieved. Finding the optimum 
pH for a separation is a key part of method development. In case of silica columns, 
extreme pH values, very high or very low should be avoided, to prevent shortening of 
column life time.  
           Nonionized analytes have better retention (that is acids at low pH and bases at 
high pH). However, it is not necessary to fully suppress ionization for success with 
HPLC; 90% suppression is generally considered adequate when sufficient buffer 
capacity is employed in the mobile phase. Silanols on silica ionize at mid pH and 
higher, increasing retention of the basic analytes (that is possible ion-exchange 
interactions). 
         The buffering capacity of any mobile phase is related to the prepared molarity 
and how close the desired eluent pH is to the pK of the buffering ion.  
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 Diluent: 
        In case of HPLC, it is necessary to remember that sample diluent is more than 
just a solubilizing agent for the active pharmaceutical ingredient, and one must 
consider the importance of the diluent for solubilizing impurities, acceptable peak 
shape quality, analyte stability, and analyte–surface compatibility. The diluent should 
be compatible and miscible with mobile phase. 
          The strength of the diluent should be less than that of the mobile phase in order 
to prevent distorted peak shapes, including tailing, fronting, flat-top, shoulders or split 
peaks. 
 Detectors 
Ultraviolet/visible (UV/vis) absorption spectrophotometers are commonly 
used detectors in pharmaceutical analysis. In specific cases fluorescence 
spectrophotometers, differential refractometers (RI), electrochemical detectors, 
evaporative light-scattering detectors (ELSD), charged aerosol detectors (CAD), mass 
spectrometers (MS) or other special detectors may be used. Where an analyte 
possesses a chromophore that absorbs UV/vis radiation, the UV/vis detector is the 
first choice because of its favorable signal to noise ratio. Such a detector is not 
suitable for detecting analytes with very weak chromophores. 
A variant on the UV/vis type of detector, which can furnish detailed spectral 
information, is the diode array spectrophotometer. This type of detector acquires 
absorbance data over a certain UV/vis range and can provide chromatograms at 
multiple, selectable wavelengths, together with spectra for the eluted peaks. In 
addition, the detector and accompanying computer programs can be used to assess the 
spectral homogeneity of peaks, which may provide information on the 
chromatographic purity of the peaks. This can be especially useful in method 
development and validation.       
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Figure 2: Variable Wavelength UV Detector 
 
Figure 3: Photodiode Array Detector 
HPLC Efficiency Parameters 
 System suitability criteria:   
 
The theory of chromatography has been used as the basis for System-
Suitability tests, which are set of quantitative criteria that test the suitability of the 
chromatographic system to identify and quantify drug related samples by HPLC at 
any step of the pharmaceutical analysis.   
 
Retention Time (tR), Capacity Factor (k') and Relative Retention Time (RRT)  
The time elapsed between the injection of the sample components into the 
column and their detection is known as the Retention Time (tR).   The retention time is 
longer when the solute has higher affinity to the stationary phase due to its chemical 
nature.  For example, in reverse phase chromatography, the more lypophilic 
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compounds are retained longer.  Therefore, the retention time is a property of the 
analyte that can be used for its identification. 
 
 A non-retained substance passes through the column at a time t0, called the Void 
Time.  The Retention Factor or Capacity Factor k' of an analyte is measured 
experimentally as shown in Eq(1a) and Eq(1b): 
                                                   
 Eqn.1a
                    
                                       
                 
 
             
The Capacity Factor describes the thermodynamic basis of the separation and 
its definition is the ratio of the amounts of the solute at the stationary and mobile 
phases within the analyte band inside the chromatographic column:   
                                                                                                                            
Eqn.1b
        
                                               
 
 
Where, 
       
          Cs is the concentration of the solute at the stationary phase  
          Cm is its concentration at the mobile phase and 
           Φ is the ratio of the stationary and mobile phase volumes all within the 
chromatographic band.  
 
The Retention Factor (Eqn 1a) is used to compare the retention of a solute 
between two chromatographic systems, normalizing it to the column's geometry and 
system flow rate. 
 
 The need to determine the void time can be tricky sometimes, due to the 
instability of the elution time of the void time marker, t0, therefore, when the 
chromatogram is complex in nature, and one known component is always present at a 
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certain retention time, it can be used as a retention marker for other peaks.  In such 
cases the ratio between the retention time of any peak in the chromatogram and the 
retention time of the marker is used (tA (Peak) / tM (Marker)) and referred to as the Relative 
Retention Time (figure 4).  RRT is also used instead of the capacity ratio for the 
identification of the analyte as well as to compare its extent of retention in two 
different chromatographic systems.  
 
                                   
 
                                     Figure 4: Relative retention time 
Efficiency: Plate Count N and Peak Capacity Pc 
 
The efficiency is calculated in terms of HEPT (Height Equivalent Theoretical 
Plate) and Theoretical plate count. The sharpness of a peak relative to its retention 
time is a measure of the system's efficiency, calculated as N, plate count.  Band-
broadening phenomena in the column such as eddy diffusion, molecular diffusion, 
and mass-transfer kinetics and extra-column effects reduce the efficiency of the 
separation.  The sharpness of a peak is relevant to the limit of detection and limit of 
quantification of the chromatographic system.  The sharper the peak for a specific 
area, the better is its signal-to-noise; hence the system is capable of detecting lower 
concentrations.   Therefore, the efficiency of the chromatographic system must be 
established by the system suitability test before the analysis of low concentrations 
that requires high sensitivity of the system, such as the analysis of drug impurities 
and degradation products. 
 
The efficiency of the separation is determined by the Plate Count N when 
working at isocratic conditions, whereas it is usually measured by Peak Capacity Pc 
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when working at gradient conditions.  The following equation for the plate count is 
used by the United States Pharmacopoeia (USP) to calculate N. 
 
 
Eqn. 2                     
Where, 
                w is measured from the baseline peak width calculated using lines tangent to 
the peak width at 50 % height(Wh) in figure(5), 
                t or tR  is retention time of considered compound peak 
 
Eqn 3                    
 
 
                                  
    Figure: 5 Plate count 
Peak Capacity Pc is defined as number of peaks that can be separated within a 
retention window for a specific pre-determined resolution. In other words, it is the 
runtime measured in peak width units.   It is assumed that peaks occur over the 
gradient chromatogram. Therefore, Peak Capacity can be calculated from the peak 
widths w in the chromatogram as follows: 
Eqn. 4:                   
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Where n is the number of peaks at the segment of the gradient selected for the 
calculation, tg. Thus peak capacity can be simply the gradient run time divided by the 
average peak width.   The sharper the peaks the higher is the peak capacity, hence the 
system should be able to resolve more peaks at the selected run time as well as detect 
lower concentrations. 
 
Another measure of the column's chromatographic efficiency is the Height 
Equivalent to Theoretical Plate (HETP) which is calculated from the following 
equation: 
 
Eqn 5:                   HETP = (L/N)  
 
Where L is column length and N is the plate count. 
 
Selectivity Factor (alfa) and Resolution Factor Rs  
 
The separation is a function of the thermodynamics of the system. Substances 
are separated in a chromatographic column when their rate of migration differs, due to 
their different distribution between the stationary and mobile phases.  The Selectivity 
Factor (α), and Resolution Factor (Rs), measure the extent of separation between two 
adjacent peaks.  The Selectivity Factor accounts only for the ratio of the Retention 
Factors, k', of the two peaks (k'2/k'1), whereas the Resolution Factor, Rs, accounts for 
the difference between the retention times of the two peaks relative to their width. 
 
The equation that describes the experimental measurement of the Resolution 
Factor, Rs, is as follows: 
 
                                                    Rs =     Rt1 – Rt2 
                                                             0.5 (W1+W2) 
 
Where tR is the retention time of peaks 1 and 2 respectively and w is their 
respective peak width at the tangents' baseline.  According to the pharmacopeias Rs 
should be above 1.5 for an accurate quantitative measurement.   Figure 4 shows that 
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the resolution measured between every two adjacent peaks in the chromatogram was 
above 1.5, therefore, it was above the minimum required.   
 
The resolution is a critical value when working with complex samples such as 
drug impurities and degradation products, or when the formulation is complex and 
excipients might interfere with the quantitative measurements.  Therefore, it is an 
essential part of the system suitability measurement stage before the quantitative work 
of these type of samples.   
 
The sample used for the measurements of Rs during the system suitability runs 
is sometimes called Resolution Solution. It usually contains the components that are 
the most difficult to resolve.  
 
The theoretical description of the Resolution Factor Rs is shown in following 
equation.  It includes some of the above parameters, the plate count N, the selectivity 
and the average of the two peaks' capacity factors k':  
 
                                                         
 
It can be clearly seen from this equation that the plate count is the most 
effecting parameter in the increase of the chromatographic resolution.  Since the plate 
count increases with the reduction in particle diameter, it explains the reduction in 
particle diameter of the stationary phase material during the last 3 decades of HPLC.   
 
Peak Asymmetry Factor Af and Tailing Factor T 
 
The chromatographic peak is assumed to have a Gaussian shape under ideal 
conditions, describing normal distribution of the velocity of the molecules populating 
the peak zone migrating through the stationary phase inside the column.  Any 
deviation from the normal distribution indicates non-ideality of the distribution and 
the migration process therefore might jeopardize the integrity of the peak's 
integration, reducing the accuracy of the quantitation.  This is the reason why USP 
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Tailing is a peak's parameter almost always measured in the system suitability step of 
the analysis.   
 
The deviation from symmetry is measured by the Asymmetry 
Factor, Af or Tailing Factor T.  The calculation of Asymmetry Factor, Af is described 
by the following equation: 
 
Eqn 6                     
 
Where A and B are sections in the horizontal line parallel to the baseline, 
drawn at 10% of the peak height as shown in Figure 6a.  
  
The calculation of Tailing Factor, T, which is more widely used in the 
pharmaceutical industry, as suggested by the pharmacopeias, is described by the 
following equation: 
 
Eqn 7                     
 
Where A and B are sections in the horizontal line parallel to the baseline, 
drawn at 5% of the peak height, as also shown in Figure 6b.  The USP suggests that 
Tailing Factor should be in the range of 0.5 up to 2 to assure a precise and accurate 
quantitative measurement.                                                                                        
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Figure: 6a Asymmetry factor 
  
 
                                                      Figure: 6b Tailing factor 
 
Table No: 1 validation parameters as per ICH guidelines and USP 
1.  Specificity 5. Limit of Detection 
2.  Linearity  &  Range 6. Limit of Quantitation 
3. Accuracy 7. Robustness 
4. Precision 8. System Suitability 
 
 Specificity  
The determination of method specificity can be achieved in two ways, first 
and most desirable, all potential interfering compounds can be tested to demonstrate 
their separation from the peak (S) of interest with a specified resolution (usually RS ≥ 
2) A second method for achieving a specificity is the use of selective detectors 
especially for co eluting compounds. For example a selective detectors (e.g. 
electrochemical and radioactivity) will respond some compounds but not to others. 
 Linearity  
The linearity of a method is to measure a calibration plot of area Vs 
concentration approximates a straight line. Linearity can be assessed by performing 
single measurements at several analyte concentrations. The data are then processed 
using a linear least-squares regression. The resulting plot slope, intercept, and 
correlation coefficient provide the desired information on linearity. 
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 The numerical value of the slope and intercept will depend on the response 
measured, but intercepts greater than 2% (relative to the target level response) are 
typically expected with well-designed HPLC methods for major component analysis. 
This approach involves determining the response factor (or sensitivity) Vs analyte 
concentration (or log concentration for a wide range). This response factor (RF) is 
calculated as   
                                 RF = DR/C  
Where DR is the detector response (peak area or peak height) and C is the 
concentration of the analyte. 
 Range 
The range of method can be defined as the lower and upper concentrations for 
which the analytical method has adequate accuracy, precision, and linearity. The 
range of concentrations examined will depend on the type of method and its use. 
 Accuracy   
 A sample (whose “true value” is known) is analyzed and the measured value 
should ideally be identical to the true value with high accuracy,. Typically, accuracy 
is represented and determined by recovery studies, but there are three ways to 
determine accuracy: 
1) Comparison to a reference standard 
2) Recovery of the analyte spiked into blank matrix, or 
3) Standard addition of the analyte. 
             Accuracy determination for an HPLC method should be carried out with a 
minimum of nine measurements using at least three concentrations. This approach 
minimizes any variability and/or bias in sample preparation technique and analysis for 
one sample at only one concentration.  
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 Precision 
Repeatability, intermediate precision and reproducibility.  
 Repeatability 
Repeatability is the precision of a method under same operating conditions 
over a short period of time. One aspect of this is instrument precision. This is 
measured by the sequential, repetitive injection of the same homogenous sample 
(typically, 10 or more times), followed by the averaging of the peak area or peak-
height values and determination of the relative standard deviation of all injections. A 
second aspect is sometimes termed intra-assay precision and involves multiple 
measurements of the same sample (different preparation) by the same analyst under 
the same conditions. 
 Intermediate precision 
 It is the agreement of complete measurements (including standards) when the 
same method is applied many times within the same laboratory. This can include 
multiple preparations of samples and standards were analysis on different days, 
instruments. or analysts to confirm reproducibility. 
 Reproducibility 
 The precision assessment during initial method validation often applies to the 
first two of these: repeatability and intermediate precision. Reproducibility is usually 
determined during method transfer or crossover to another laboratory or location. 
Precision often is expressed by the standard deviation (SD) or relative standard 
deviation (RSD) of a data set. If a set of n measurements is defined as  
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Where xi are the individual measurements on the sample . The standard 
deviation of these data is then 
 
And the relative standard deviation (RSD) or coefficient of variation (CV) is 
                                            RSD (%) = 100 SD / x 
           Where SD= Standard deviation, X= average 
Limit of Detection and Limit of Quantitation 
  The Limit of Detection (LOD) can be defined as the smallest level of analyte 
that gives a measurable response. 
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DRUG PROFILE  
VITAMIN E  
 
Name   : d-Alpha Tocopheryl acetate 
 
Source: Corn oil, Soyabean oil and margarine 
 
Uses     : Anti-oxidant 
 
Molecular Structure: 
 
 
Vitamin E refers to a group of eight fat-soluble compounds that include 
bothtocopherols and to cotrienols. There are many different forms of vitamin E, of 
which γ-tocopherol is the most common in the North American diet. γ-Tocopherol 
can be found in corn oil, soybean oil, margarine and dressings. α-Tocopherol, the 
most biologically active form of vitamin E, is the second most common form of 
vitamin E in the North American diet. This variant of vitamin E can be found most 
abundantly in wheat germ oil, sunflower, and safflower oils. It is a fat-
soluble antioxidant that stops the production of reactive oxygen species formed when 
fat undergoes oxidation.  
 
PHARAMACOLOGICAL ACTION AND USE: 
            Vitamin E has many biological functions. The antioxidant function is 
considered to be the most important function of vitamin E and is the one it is best 
known for. As it is fat-soluble, it is incorporated into cell membranes, which protects 
them from oxidative damage. However, there are other functions that have also been 
recognized to be of importance. α-Tocopherol has a regulatory effect on enzymatic 
activities. For instance, protein kinase C (PKC), which plays a role in smooth muscle 
growth, can be inhibited by α-tocopherol. α-Tocopherol has a stimulatory effect on 
the dephosphorylation enzyme, protein phosphatase 2A, which in turn, cleaves 
phosphate groups from PKC leading to its deactivation, bringing the smooth muscle 
growth to a halt. Vitamin E also has an effect on gene expression. Macrophages rich 
in cholesterol are found in the atherogenetic tissue. Scavenger receptor CD36 is a 
class B scavenger receptor found to be up-regulated by oxidized low density 
lipoprotein (LDL) and binds it. Treatment with alpha tocopherol was found to down 
regulate the CD36 scavenger receptor gene expression as well as the scavenger 
receptor class A (SR-A). In addition to the effect it has been shown to have on SRA 
and CD36, α-tocopherol also has an effect on expression of the connective tissue 
growth factor (CTGF).CTGF gene, when expressed, is responsible for the repair of 
the wounds and regeneration of the extracellular tissue that is lost or damaged during 
atherosclerosis. Moreover, vitamin E also plays a role in neurological functions, and 
inhibition of platelet aggregation and it has even been suggested that the most 
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important function of vitamin E is as a signaling molecule, and that it has no 
significant role in antioxidant metabolism. 
Vitamin E deficiency can cause: 
Spino cerebellar ataxia, Myopathies, Peripheral neuropathy, Ataxia, Skeletal 
myopathies, Retinopathy and Impairment of the immune response 
 
UBIDECARENONE 
 
                                                           
IUPAC name  
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-
Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-
methylcyclohexa-2,5-diene-1,4-dione 
Chemical properties 
The oxidized structure of CoQ10 is shown on the top-right. The various kinds of 
Coenzyme Q may be distinguished by the number of isoprenoid subunits in their side-
chains. The most common Coenzyme Q in human mitochondria is CoQ10. Q refers to 
the quinone head and 10 refers to the number of isoprene repeats in the tail. The 
molecule below has three isoprenoid units and would be called Q3. 
Absorption 
CoQ10 is a crystalline powder insoluble in water. Absorption follows the same process 
as that of lipids; the uptake mechanism appears to be similar to that of vitamin E, 
another lipid-soluble nutrient. This process in the human body involves secretion into 
the small intestine of pancreatic enzymes and bile, which facilitates emulsification 
and micelle formation required for absorption of lipophilic substances. Food intake 
(and the presence of lipids) stimulates bodily biliary excretion of bile acids and 
greatly enhances absorption of CoQ10. Exogenous CoQ10 is absorbed from the small 
intestine and is best absorbed if taken with a meal. Serum concentration of CoQ10 in 
fed condition is higher than in fasting conditions.  
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Metabolism[edit] 
Data on the metabolism of CoQ10 in animals and humans are limited. A study with 
14C-labeled CoQ10 in rats showed most of the radioactivity in the liver two hours after 
oral administration when the peak plasma radioactivity was observed, but it should be 
noted that CoQ9 (with only 9 isoprenyl units) is the predominant form of coenzyme Q 
in rats. It appears that CoQ10 is metabolised in all tissues, while a major route for its 
elimination is biliary and fecal excretion. After the withdrawal of CoQ10 
supplementation, the levels return to normal within a few days, irrespective of the 
type of formulation used.  
 
PHARAMACOLOGICAL ACTION AND USE: 
The antioxidant nature of CoQ10 derives from its energy carrier function. As an 
energy carrier, the CoQ10 molecule continuously goes through an oxidation–reduction 
cycle. As it accepts electrons, it becomes reduced. As it gives up electrons, it becomes 
oxidized. In its reduced form, the CoQ10 molecule holds electrons rather loosely, so 
this CoQ molecule will give up one or both electrons quite easily and, thus, act as an 
antioxidant. CoQ10 inhibits lipid peroxidation by preventing the production of lipid 
peroxyl radicals (LOO). Moreover, CoQH2 reduces the initial perferryl radical and 
singlet oxygen, with concomitant formation of ubisemiquinone and H2O2. This 
quenching of the initiating perferryl radicals, which prevent propagation of lipid 
peroxidation, protects not only lipids, but also proteins from oxidation. In addition, 
the reduced form of CoQ effectively regenerates vitamin E from the a-tocopheroxyl 
radical, thereby interfering with the propagation step. Furthermore, during oxidative 
stress, interaction of H2O2 with metal ions bound to DNA generates hydroxyl radicals, 
and CoQ efficiently prevents the oxidation of bases, in particular, in mitochondrial 
DNA. In contrast to other antioxidants, this compound inhibits both the initiation and 
the propagation of lipid and protein oxidation. It also regenerates other antioxidants 
such as vitamin E. The circulating CoQ10 in LDL prevents oxidation of LDL, which 
may provide benefit in cardiovascular diseases. 
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AIM AND OBJECTIVE OF STUDY 
Aim 
Development and Validation of Stability Indicating Assay Method of 
Ubidecarenone and Vitamin E in pharmaceutical dosage forms by HPLC. 
Objective 
• To develop a simple Stability Indicating Assay Method (SIAM) which can 
detect and quantify easily. 
• To develop a Precise, Linear Accurate and Rugged method. 
• Through this project, an attempt is being made to develop and validate simple, 
cost effective, sensitive methods for quantitative monitoring of Paracetamol, 
Aceclofenac and Tramadol in pure as well as tablet dosage forms. 
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REVIEW OF LITERATURE 
 
• Johanna k lang et al developed a quantitative high-performance liquid 
chromatographic (HPLC) assay for the simultaneous determination of vitamin E 
isomers (alpha-, gamma- and delta-tocopherol), oxidized coenzyme Q species 
(ubiquinone 9, ubiquinone 10) and reduced coenzyme Q homologues (ubiquinol 9, 
ubiquinol 10) in various tissues, including blood and plasma. The compounds of 
interest are quantitatively extracted with a fast one-step lipid extraction procedure and 
subjected to HPLC without further purification. The extract is separated on a 
reversed-phase column and the eluted compounds are monitored by sequential UV 
and electrochemical detection. Ubiquinones are detected at their 275 nm absorbance 
maximum, by the UV detector, whereas tocopherols and ubiquinols are monitored by 
the electrochemical detector with high sensitivity and selectivity.  
 
• Beatrice Gleizie et al developed a HPLC methods for fat-soluble vitamins (such as 
vitamins A and E) and lipid microconstituents (such as carotenoids). However, high-
performance liquid chromatography (HPLC) methods able to detect these molecules 
in simultaneous runs are often difficult to set up. They reported here a 35-min 
reversed-phase HPLC method using a single C30 column kept at 35°C with a gradient 
system of methanol, methyl-tert-butyl ether and water at a flow-rate of 1 mL/min.  
 
• Eman S. El-Leithy et al developed a method for estimation of TC and CoQ10 were 
formulated as solid lipid nanoparticles (SLNs). The study was focused on establishing 
and validating a simple and reproducible spectrophotometric method for simultaneous 
determination of TC and CoQ10 in their binary mixture or pharmaceutical dosage 
forms. A new method based on simultaneous estimation of drug mixture without prior 
separation was developed. The TC and CoQ10 were quantified at absorptivity 
wavelengths of 236 nm and 275 nm, respectively. Calibration curves obeyed Beer's 
law in range of 2–14 µg/ml with a correlation coefficient (R2) of 0.999 in both 
methanol and simplified simulated intestinal fluid (SSIF).  
 
• Dalibor Šatínský et al developed a high-performance liquid chromatography 
(HPLC) method for quantitative determination of vitamin E acetate in dietary 
supplements. Commercial samples of dietary supplements were extracted 
with 100 % methanol with the help of ultrasound bath. A 20-µL sample 
volume of the filtered solution was directly injected into the HPLC system. 
Separation of ballast matrix, vitamin E acetate, and internal standard 
cholecalciferol was performed on the monolithic column Chromolith 
Performance RP-18e column (100 × 4.6 mm) with mobile phase 
methanol/water (98:2, v/v) at a flow rate of 2.0 mL min−1 and at temperature 
30 °C. The detector was set at 290 nm.  
 
• Claudia Cristina Ferreiro-Barros et al developed a method to extract the total levels of 
CoQ10 in human plasma through the Ultra High Performance Liquid Chromatography 
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(UHPLC). By this method Two extraction protocols were tested: a) methanol: hexane 
and b) 1-propanol. The following parameters were analyzed: extraction temperature 
(19ºC and 4ºC), extraction tubes (glass and polypropylene), and surfactants (SDS, 
Triton X-100, Tween-20) at different concentrations, i.e., 1%, 3%, 5% and 10%. 
 
• Mark Roman et al developed a high-performance liquid chromatographic (HPLC)-UV 
method for the determination of coenzyme Q10 (CoQ10, ubidecarenone) in raw 
materials and dietary supplements. Ten collaborating laboratories determined the total 
CoQ10 content in 8 blind duplicate samples. Sample materials included CoQ10 raw 
material and 4 finished product dietary supplements representing softgels, hardshell 
gelatin capsules, and chewable wafers. In addition, collaborating laboratories received 
a negative control and negative control spiked with CoQ10 at low and high levels to 
determine recovery. Materials were extracted with an acetonitrile–tetrahydrofuran–
water mixture. Ferric chloride was added to the test solutions to ensure all CoQ10 was 
in the oxidized form. The HPLC analyses were performed on a C18 column using UV 
detection at 275 nm.  
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METHODOLOGY 
 
HPLC Method 
 
Materials 
All The Chemicals and reagents used in the investigation were of analytical grade, 
which are 
• Vitamin E WS obtained from M/S Softgel Health Care Ltd., Chennai 
• Ubidecarenone WS obtained from M/S Softgel Health Care Ltd., Chennai 
• Methanol obtained from Rankem Chemicals, Mumbai. 
• Ethanol obtained from Changsu Hongshong Chemicals, China 
• Commercially available marketed dosage forms 
• PRO Q Soft gelatin Capsules manufactured by Softgel Health Care pvt Ltd., it 
contains 50.0 mg of Ubidecarenone, 12.5 mg of Vitamin E. 
 
OPTIMISED METHOD 
 
Principle: 
Separation and quantification based on the isocratic reverse phase chromatography 
with UV detection.  
•  
Chromatographic Conditions: 
 
 
Mobile phase Preparation: 
Ethanol: Methanol in 50:50 ratio and sonicate to degas 
 
Diluent: Use mobile phase as diluent 
 
Preparation of Standard solution: 
Solution-A: 
Weigh 125.0mg of Vitamin E into 100ml volumetric flask, add 30mL of diluent and 
sonicate for 5 minutes until dissolves and make upto volume with diluent. 
 
Solution-B: 
Weigh 50 mg of Ubidecarenone WS/RS and transfer into 100mL volumetric flask and 
add 5 mL of n-Hexane, sonicate for 5 minutes until dissolves and add 10mL of 
Solution-A. Add 30 mL of diluent sonicate for 5 minutes, make upto the volume with 
diluent.  
 
Preparation of Sample solution: 
Cut open about 20 capsules and collect the medicament in a clean petridish. Mix well 
and weigh about 500 mg of medicament  into a 100mL volumetric flask, add 5 mL of 
Instrument - HPLC with UV /PDA detector 
Column - C18, 4.6-mm x 250-mm;5µ (Zodiac or Equivalent) 
Flow rate - 1.5 mL/min 
Column temperature - 40°C 
Wavelength - 275nm 
Injection volume - 20µl 
Run time - 30minutes 
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n-Hexane, sonicate for 20minutes with intermediate shaking until dissolve, add 30mL 
of diluent, shake well for 20 minutes and makeup the volume with diluent, filter the 
solution through 0.45µ nylon filter and inject. 
 
SPECIFICITY: 
 “Specificity is the ability of the method to measure the analyte in the presence of 
matrix components. Demonstrate the specificity by identification of analyte, blank 
and placebo interference and Peak purity of analyte.” 
 
Prepare the following solutions for Specificity 
 
1) Blank (Diluent): Refer Method description 
2) Placebo Preparation:  
Collected the placebo in a clean petridish. Mixed well and weighed about 
432.3 mg of medicament  into a 100mL volumetric flask, added 5 mL of n-
Hexane, sonicated for 20minutes with intermediate shaking until dissolve, 
added 30mL of diluent, shaken well for 20 minutes and makeup the volume 
with diluent, filtered the solution through 0.45µ nylon filter and injected. 
3) Prepare standard as per Method description 
4) Prepare sample as per Method description  
 
Forced Degradation / Exposure Study: 
 
• Following stress conditions are generally adopted during forced degradation study, 
but conditions can be decided and optimized based on physiochemical properties of 
drug substance, available literature and amount of degradation achieved during study.  
 
Following are the general parameters for different stress conditions 
 
Acid Hydrolysis: 
• Weighed 500.0mg of medicament, 432.3mg of medicament placebo respectively in 
separate reflux flasks as per test method. Added about 10mL to 20mL ml of 0.1 N 
Hydrochloric acid to the flask and refluxed. After refluxing, cooled the sample and added 
same quantity of 0.1N Sodium Hydroxide so as to neutralize the solution. Transferred 
contents into a 100 mL volumetric flask, added 5 mL of n-Hexane, sonicate for 20minutes 
with intermediate shaking until dissolve, added 30mL of diluent, shaken well for 20 
minutes and makeup the volume with diluent, filter the solution through 0.45µ nylon filter 
and inject. 
•  Prepared the blank solution as per above preparation. 
• Injected blank, Placebo, unstressed sample and degradation sample into the HPLC 
system with photo diode array detector as per the test method and calculated the net 
degradation. 
• Also main analyte peak shall be confirmed for its purity index. 
 
Base Hydrolysis: 
• Weighed 500.0mg of medicament, 432.3mg of medicament placebo respectively in 
separate reflux flasks as per test method. Added about 10mL to 20mL ml of 0.1 N 
Sodium Hydroxide to the flask and refluxed. After refluxing, cooled the sample 
and added same quantity of 0.1 N Hydrochloric acid so as to neutralize the 
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solution. Transferred contents into a 100 mL volumetric flask, added 5 mL of n-
Hexane, sonicated for 20minutes with intermediate shaking until dissolve, added 30mL of 
diluent, shake well for 20 minutes and makeup the volume with diluent, filter the solution 
through 0.45µ nylon filter and inject. 
• Prepared the blank solution as per above preparation. 
• Injectd blank, Placebo, unstressed sample and degradation sample into the HPLC 
system with photo diode array detector as per the test method and calculate the net 
degradation. 
• Also main analyte peak shall be confirmed for its purity index 
 
Oxidation with Hydrogen Peroxide: 
• Weighed 500.0mg of medicament, 432.3mg of medicament placebo respectively 
in separate reflux flasks as per test method. Added about 10 ml to 20 ml of 1% of 
Hydrogen peroxide to the flask and refluxed. After refluxing, cooled the sample 
and transfer contents into a 100 mL volumetric flask, added 5 mL of n-Hexane, 
sonicated for 20minutes with intermediate shaking until dissolve, add 30mL of diluent, 
shaken well for 20 minutes and makeup the volume with diluent, filter the solution 
through 0.45µ nylon filter and inject. 
• Prepare the blank solution as per above preparation. 
• Injected blank, Placebo, unstressed and degradation sample into the HPLC system 
with photo diode array detector as per the test method and calculate the net 
degradation. 
• Also main analyte peak shall be confirmed for its purity index 
 
Heat: 
• Drug product and placebo shall be exposed to heat at 105 0C. 
• Weighed 500.0mg of medicament, 432.3mg of medicament placebo which are 
exposed to heat, respectively in a separate flask and prepared the samples as per test 
method.  
• Injected blank, standard solution, unstressed sample and stressed sample into the 
HPLC system with photo diode array detector as per the test method and calculated 
the net degradation. 
• Also main analyte peak shall be confirmed for its purity index.  
 
Water Hydrolysis: 
• Weighed 500.0mg of medicament, 432.3mg of medicament placebo respectively 
in separate reflux flasks as per test method. Added about 10 ml to 20 ml of water 
to the flask and refluxed. After refluxing, cooled the sample and transferred 
contents into a 100 mL volumetric flask, added 5 mL of n-Hexane, sonicated for 
20minutes with intermediate shaking until dissolve, added 30mL of diluent, shaken well 
for 20 minutes and makeup the volume with diluent, filter the solution through 0.45µ 
nylon filter and inject. 
• Prepare the blank solution as per above preparation. 
• Injected blank, Placebo, unstressed sample and degradation sample into the HPLC 
system with photo diode array detector as per the test method and calculate the net 
degradation. 
• Also main analyte peak shall be confirmed for its purity index 
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Humidity: 
• Drug product and placebo shall be exposed to humidity i.e. 90% RH and 25°C in a 
desiccator at least for 7 days. 
• Weighed 500.0 mg of medicament and 432.3 mg of placebo exposed to humidity, 
respectively in a separate flask and prepare the samples as per test method.  
• Injected blank, standard solution, unstressed sample and stressed sample into the 
HPLC system with photodiode array detector as per the test method and calculated 
the net degradation. 
• Also main analyte peak shall be confirmed for its purity. 
 
Linearity:  
The ability of the method to produce results is directly proportional to the 
concentration of the analyte in samples within a given range. 
 
Range: 
It is the interval between the upper and lower concentration of analyte for which it has 
been demonstrated that the analytical method has a suitable level of precision, 
accuracy and linearity. 
 
Performed the linearity in the concentrations of 50.0%, 75.0%, 100.0%, 125.0% and 
150.0% of working concentration of Vitamin E and Ubidecarenone.   
 
Record the average area for each level and calculate slope, y- intercept and correlation 
coefficient. 
Plot the graph of respective analyte peak concentration on X- axis and area response 
on Y-axis. 
 
Preparation of Standard solution: 
Solution-A: 
Weighed 125.0mg of Vitamin E into 100ml volumetric flask, added 30mL of diluent 
and sonicated for 5 minutes until dissolves and make upto volume with diluent. 
Solution-B: 
Weighed 50 mg of Ubidecarenone WS/RS and transferred into 100mL volumetric 
flask and added 5 mL of n-Hexane, sonicated for 5 minutes until dissolves and added 
10mL of Solution-A. Added 30 mL of diluent sonicate for 5 minutes, make upto the 
volume with diluent.  
 
Preparation of Linearity Standard stock solution:  
Solution-I: 
Weighed 125.0mg of Vitamin E into 100ml volumetric flask, added 30mL of diluent 
and sonicated for 5 minutes until dissolves and make upto volume with diluent. 
 
Solution-II: 
Weighed 500 mg of Ubidecarenone WS/RS and transferred into 100mL volumetric 
flask and added 5 mL of n-Hexane, sonicated for 5 minutes until dissolves and added 
30 mL of diluent sonicated for 5 minutes, make upto the volume with diluent. 
 
Preparation of Linearity Solutions: 
 1) 50.0% solution:             
Pipetted out 5.0 ml of Solution-I and Solution-II into 100 ml volumetric flask and 
make up to volume with diluent.   
   
 2) 75.0% solution:             
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Pipetted 7.5mL of Solution-I and Solution-II into 100 ml volumetric flask and make 
up to volume with diluent.   
 
3) 100.0% solution:             
Pipetted out 10.0 mL Solution-I and Solution-II into 100 ml volumetric flask and 
make up to volume with diluent.   
  4) 125.0% solution:             
Pipetted 12.5mL Solution-I and Solution-II into 100 ml volumetric flask and make up 
to volume with diluent. 
 
  5) 150.0% solution:             
Pipette d15.0mL Solution-I and Solution-II into 100 ml volumetric flask and make up 
to volume with diluent.  
 
Accuracy: 
 
Accuracy is the closeness of the test results obtained by the method to the true value.  
Accuracy may often be expressed as percent recovery by the Assay of known, added 
amounts of analyte. Accuracy is a measure of the exactness of analytical method. 
 
 
Accuracy shall be assessed using ‘3’ concentration (50.0%, 100.0% and 150.0%). 
 
The active can be added as solution to placebo at 50.0%, 100.0% and 150.0% 
concentration. Perform assay for each subsequent mixture. At each concentration, the 
average result shall then be expressed as a percentage of the amount recovered to 
determine the recovery at each level or concentration. 
 
Solution-A: 
Weighed 125.0mg of Vitamin E into 100ml volumetric flask, added 30mL of diluent 
and sonicated for 5 minutes until dissolves and make upto volume with diluent. 
Solution-B: 
Weighed 50 mg of Ubidecarenone WS/RS and transferred into 100mL volumetric 
flask and added 5 mL of n-Hexane, sonicated for 5 minutes until dissolves and added 
10mL of Solution-A. Added 30 mL of diluent sonicate for 5 minutes, make upto the 
volume with diluent.  
 
Preparation of Accuracy Standard stock solution: 
Solution-I: 
Weighed 125.0mg of Vitamin E into 100ml volumetric flask, added 30mL of diluent 
and sonicated for 5 minutes until dissolves and make upto volume with diluent. 
 
Solution-II: 
Weighed 500 mg of Ubidecarenone WS/RS and transfer into 100mL volumetric flask 
and added 5 mL of n-Hexane, sonicate for 5 minutes until dissolves and added 30 mL 
of diluent sonicated for 5 minutes, make upto the volume with diluent. 
 
Note: Prepared the below test solutions in triplicate 
 
Accuracy 50% solution: 
Mixed well and weighed about 432.3 mg of medicament placebo into a 100mL 
volumetric flask, added 5.0mL of each of Solution-I and Solution-II and sonicate for 
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20minutes with intermediate shaking until dissolve, added 30mL of diluent, shaken 
well for 20 minutes and makeup the volume with diluent, filtered the solution through 
0.45µ nylon filter and inject. 
 
Accuracy 100% solution: 
Mixed well and weighed about 432.3 mg of medicament placebo into a 100mL 
volumetric flask, added 10.0mL of each of Solution-I and Solution-II and sonicate for 
20minutes with intermediate shaking until dissolve, added 30mL of diluent, shaken 
well for 20 minutes and makeup the volume with diluent, filtered the solution through 
0.45µ nylon filter and inject. 
 
 
Accuracy 150% solution: 
Mixed well and weighed about 432.3 mg of medicament placebo into a 100mL 
volumetric flask, added 15.0mL of each of Solution-I and Solution-II and sonicate for 
20minutes with intermediate shaking until dissolve, added 30mL of diluent, shaken 
well for 20 minutes and makeup the volume with diluent, filtered the solution through 
0.45µ nylon filter and inject. 
 
Precision 
Precession was measured in terms of repeatability, which was determined by 
sufficient no. of aliquots of homogeneous sample and its %RSD was calculated. 
System Precision  
System precision will be tested by injecting 6 replicate Injections of Vitamin E and 
Ubidecarenone standard solution. Calculated % RSD of peak area and RT. 
 
Method Precision 
Method precision or repeatability of solution will be demonstrated by analyzing 
“Ubidecarenone 50mg and Vitamin E 12.5mg Capsules” in 6 replicate sample 
preparations. 
 
Intermediate Precision 
Intermediate precision will be demonstrated by analyzing same batch as analysed as 
part of Method precision in 6 replicates for content of Vitamin E and Ubidecarenone 
in “Ubidecarenone 50mg and Vitamin E 12.5mg Capsules” in the same lab but by a 
different Analyst, using a different Instrument, different column and on a different 
day. 
 
 
Ruggedness  
The Ruggedness has been demonstrated by injecting six samples prepared as per the 
test preparation given in the method of analysis on two different days, by two 
different analysts and on different system (minimum two different system).Calculate 
the mean, standard deviation, relative standard deviation and confidence limits from 
six test preparations. 
 
Robustness 
The robustness of the analytical method for Content of Vitamin E and Ubidecarenone 
in “Ubidecarenone 50mg and Vitamin E 12.5mg Capsules” by performing the method 
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with small but deliberate variations in flow rate (±0.2 mL), column oven temperature 
(±2°C) and wavelength (±2 nm). 
 
Filter validation: 
Filter validation of the analytical method will be demonstrated by assaying the 
homogeneous sample (without filtration and with filtration) solution. The percentage 
RSD of the test results will be calculated. 
 
Filter validation will be demonstrated by assaying the sample without filtration by 
centrifuging the sample solution, filtering through 0.45 µm nylon and through 
Whatman filter no.42 
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RESULTS 
 
1.0 PURPOSE: 
The purpose of this report is to document the data obtained during analytical 
method validation for the estimation of Content of Vitamin E and 
Ubidecarenone in “Ubidecarenone 50mg and Vitamin E12.5mg Capsules” 
(finished product) and to prove that the analytical procedure is suitable for its 
intended purpose. 
 
2.0 SCOPE: 
The scope of this report is applicable only for analytical method validation for 
Content of Ubidecarenone 50mg and Vitamin E12.5mg Capsules (finished 
product) 
3.0 PRODUCT DETAILS: 
Product Name:  Ubidecarenone 50mg and Vitamin E12.5mg Capsules (finished 
product). 
B.No.: SRT17028 
 
4.0 BACKGROUND: 
The validation of the HPLC method for the determination of Content of 
Vitamin E and Ubidecarenone in “Ubidecarenone 50mg and Vitamin E12.5mg 
Capsules” (finished product) have been carried out as per the protocol No: 
AMVP/AD/17/007-00 to ensure that the performance characteristics of the 
method meet the requirements for the Intended analytical applications. 
 
5.0 VALIDATION TEAM: 
 
DEPARTMENT RESPONSIBILITY OF VAIDATION 
Analytical Development Preparation of Report 
Quality control Review of Report 
Analytical Development Review of Report 
Quality Assurance Review of Report 
Quality Assurance Approval of Report 
 
 
6.0 PROCEDURE: 
  
6.1 The analytical method includes operational parameters and specific instructions 
such as    system suitability test, description of the blank, precautions and 
explicit formula for calculation of test results. 
 
6.2 Raw data and its preservation are part of the validation documentation 
calculations substantiating each of the applicable analytical performance 
characteristics. 
 
6.3 The procedure uses well-characterised reference materials with documented 
purity. 
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7.0 METHOD DESCRIPTION: 
 
Principle: 
Separation and quantification based on the isocratic reverse phase chromatography 
with UV detection.  
 
 
 
Chromatographic Conditions: 
 
 
 
 
 
 
 
Mobile phase Preparation: 
Ethanol: Methanol in 50:50 ratio. 
 
Diluent: Use mobile phase as diluent 
 
Preparation of Standard solution: 
Solution-A: 
Weigh 125.0mg of Vitamin E into 100ml volumetric flask, add 30mL of diluent and 
sonicate for 5 minutes until dissolves and make upto volume with diluent. 
Solution-B: 
Weigh 50 mg of Ubidecarenone WS/RS and transfer into 100mL volumetric flask and 
add 5 mL of n-Hexane, sonicate for 5 minutes until dissolves and add 10mL of 
Solution-A. Add 30 mL of diluent sonicate for 5 minutes, make upto the volume with 
diluent.  
 
Preparation of Sample solution: 
Cut open about 20 capsules and collect the medicament in a clean petridish. Mix well 
and weigh about 500 mg of medicament  into a 100mL volumetric flask, add 5 mL of 
n-Hexane, sonicate for 20minutes with intermediate shaking until dissolve, add 30mL 
of diluent, shake well for 20 minutes and makeup the volume with diluent, filter the 
solution through 0.45µ nylon filter and inject. 
 
Procedure: 
• Separately inject equal volumes (about 20 µl) of diluent as blank, six replicate 
injections of Standard preparation and two injections of two Test preparations and 
one standard injection into the chromatograph, record the chromatograms, and 
measure the responses for the major peaks.  
•  Record the chromatograms. 
Instrument - HPLC with UV /PDA detector 
Column - C18, 4.6-mm x 250-mm;5µ (Zodiac or Equivalent) 
Flow rate - 1.5 mL/min 
Column temperature - 40°C 
Wavelength - 275nm 
Injection volume - 20µl 
Run time - 30minutes 
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•  Make entry in Instrument and Column usage log book and calculate from the 
values obtained. 
 
System suitability: 
• The % RSD of areas from 6 replicate injections of standard should be NMT 2.0 
• The USP tailing factor of Vitamin E and Ubidecarenone should be NMT 2 
• The USP theoretical plate of Vitamin E and Ubidecarenone should be NLT 2000 
• The % Recovery between standard preparation and check standard  is  98.0 to 
102.0 
• The % system drift between std and bracketing standard is 97.5 to 102.5 
 
Calculation for system drift:  
Av. Area of standard X 100  
Area of Bracketing Standard 
 
Calculation: 
For Vitamin E: 
 
TA1         Swt1               10           100        SP1 
----- X --------- X ---------X ---------X-------X Avg nett wt 
SA1       100            100         Twt      100          
Where, 
SA1 - Average Peak area of Vitamin E WS/RS in standard preparation 
TA1  - Area of  Vitamin E from sample preparation 
Swt1  - Weight of Vitamin E WS/RS in standard preparation in mg 
SP1 – Potency of Vitamin E standard on as is basis. 
Twt – Weight of Sample taken for Test preparation. 
 
Content in % 
 
    Content in mg 
= --------------------------- X 100   
     Label claim 
 
For Ubidecarenone: 
 
TA2         Swt2              100          SP2 
----- X --------- X ---------X ---------X Avg nett wt 
SA2       100           Twt          100          
Where, 
SA1 - Average Peak area of Ubidecarenone WS/RS in standard preparation 
TA1  - Area of  Ubidecarenone from sample preparation 
Swt1  - Weight of Ubidecarenone WS/RS in standard preparation in mg 
SP1 – Potency of Ubidecarenone standard on as is basis. 
Twt – Weight of Sample taken for Test preparation. 
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Content in % 
 
    Content in mg 
= --------------------------- X 100   
     Label claim 
 
S.No Product Name Fill 
weight 
Label claim  
Ubidecarenone Vitamin E 
1 Ubidecarenone 50mg and Vitamin E 12.5mg Capsules 500.0 mg 50 mg 12.5 mg 
 
 
8.0 WORKING STANDARD/REFERENCE 
STANDARD/INSTRUMENT/MATERIAL: 
 
REFERENCE STANDARD /WORKING STANDARD 
 
 
Reference Standard 
/Working Standard 
Name 
Vitamin E Ubidecarenone 
Lot no. 0000280420 16F100452 
Potency 96.2 99.6 
Valid up to 20/07/17 03/11/17 
 
 
INSTRUMENT 
 
 
S.No. Name of the Instrument Code No Make Model 
1. HPLC- PDA AD/EQP/004 Shimadzu LC2030 
2. HPLC- PDA QC/EQP/126 Shimadzu LC-2010 
3. Analytical balance QC/EQP/038 Shimadzu AUW220D 
4. Analytical balance QC/EQP/039 Shimadzu AUW220D 
5. Analytical balance QC/EQP/040 Shimadzu AUW220D 
6. Column SHCA018 Waters C18 
7. Column SHCA021 Waters C18 
8. Centrifuge QC/EQP/054 Labspin TC 450 D 
9. Sonicator QC/EQP/148 PCA Analytics - 
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MATERIAL 
 
 
S.No Name Grade Manufacturer / 
Supplier 
Lot No / 
B.No 
Use Before 
1 Methanol HPLC Rankem R336B17 07/04/19 
2 Ethanol AR Changsu Hongshong 20161008 07/04/19 
3 n-Hexane HPLC Rankem R145L16 07/04/19 
 
 
 
 
9.0 VALIDATION PARAMETERS: 
 
The following parameters are considered during Analytical Method 
Validation 
 
S.No Parameter 
1.  System suitability 
2.  Specificity 
3.  Linearity and range 
4.  Accuracy 
5.  Precision 
System precision 
Method precision 
Intermediate precision (Reproducibility) 
6.  Ruggedness 
7.  Robustness 
8.  Filter Validation 
9.  Stability of Analytical solution ( Standard and sample solution) 
 
 
 
10.0 SYSTEM SUITABILITY: 
As per protocol Standard Solution of Vitamin E and Ubidecarenone is prepared 
and injected in six replicates into HPLC System. The system suitability 
parameters are calculated as per protocol and the results are tabulated as shown 
below. 
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For Vitamin E: 
No of Injection RT Response 
01 5.3 297917 
02 5.3 297741 
03 5.3 297764 
04 5.3 297575 
05 5.3 297643 
06 5.3 297660 
Mean 5.3 297717 
SD 0.0 120 
%RSD 0.1 0.0 
 
 For Ubidecarenone: 
 
No of Injection RT Response 
01 16.9 6641820 
02 16.9 6704813 
03 16.9 6686954 
04 16.9 6687865 
05 16.9 6681671 
06 16.9 6703523 
Mean 16.9 6684441 
SD 0.0 22897 
%RSD 0.0 0.3 
 
 
Acceptance criteria:   
System suitability parameters Observation Acceptance criteria Vitamin E Ubidecarenone 
The Tailing factor for Vitamin 
E and Ubidecarenone peak 
from first standard injection. 
1.0 0.9 NMT 2.0 
The Theoretical plate count for 
Vitamin E and Ubidecarenone 
peak from first standard 
injection. 
6537 8268 NLT 2000 
The %RSD for RT of Vitamin 
E and Ubidecarenone peak 
from 6 replicate injections of 
standard solution. 
0.1 0.0 NMT 1.0 
The %RSD for Peak responses 
of Vitamin E and 
Ubidecarenone peak from 6 
replicate injections of standard 
solution. 
0.0 0.3 NMT 2.0 
Conclusion:  
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The system suitability parameters are within the acceptance criteria. Hence the system 
is suitable to carry out the analysis for estimation of Content of Vitamin E and 
Ubidecarenone in “Ubidecarenone 50mg and Vitamin E 12.5mg Capsules”. During 
regular analysis, these system suitability parameters must be ensured before starting 
sample analysis. 
 
11.0 SPECIFICITY: 
As per protocol, the following solutions were prepared and injected in to HPLC 
system to establish specificity.   
 
 
1) Blank 
2) Placebo 
3) Standard solution 
4) Sample solution 
 
The results obtained are as given below 
 
Preparation RT Area Peak purity index 
 
Blank NA NA NA 
Placebo NA NA NA 
Standard solution of Vitamin E 
 
5.3 299363 0.999 
Sample solution of Vitamin E 
 
5.3 370726 1.000 
Standard solution of Ubidecarenone 
 
16.9 6721908 0.999 
Sample solution of Ubidecarenone 
 
16.9 8148923 1.000 
 
Acceptance Criteria: 
1) There should not be any interference by blank, Placebo peaks with the main 
analyte peaks. 
2) The Peak Purity index of standard peaks and sample peaks should not be less than 
0.99 (For Lab   
     Solution software) 
 
 
Conclusion:   
The result shows that there is no interference of Blank and placebo peaks at the RT of 
Vitamin E and Ubidecarenone in Sevenseas perfect7 Woman Asean Capsules. The 
peak purity index values of Vitamin E and Ubidecarenone in “Ubidecarenone 50mg 
and Vitamin E 12.5mg Capsules” for standard and sample solutions are within the 
Acceptance criteria.  
Hence it is concluded that the method is specific to estimate the amount of Vitamin E 
and Ubidecarenone in “Ubidecarenone 50mg and Vitamin E 12.5mg Capsules” 
without the interference of Blank and placebo peaks.  
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11.1  FORCED DEGRADATION STUDY: 
 11.1.1 System suitability: 
As per protocol Standard Solution of Vitamin E and Ubidecarenone is prepared 
and injected in six replicates into HPLC System. The system suitability 
parameters were calculated as per protocol and the results are tabulated as shown 
below. 
 
For Vitamin E: 
 
No of Injection RT Response 
01 5.2 316945 
02 5.2 318647 
03 5.2 319851 
04 5.2 321184 
05 5.2 321332 
06 5.2 320955 
Mean 5.2 319819 
SD 0.0 1736 
%RSD 0.0 0.5 
3 
 
 
For Ubidecarenone: 
 
No of Injection RT Response 
01 16.5 7327719 
02 16.5 7365833 
03 16.5 7338625 
04 16.6 7322775 
05 16.6 7335107 
06 16.5 7336702 
Mean 16.5 7337794 
SD 0.0 14982 
%RSD 0.0 0.2 
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Acceptance criteria:   
 
System suitability parameters Observation Acceptance 
criteria Vitamin E Ubidecarenone 
The Tailing factor for Vitamin E and 
Ubidecarenone peak from first 
standard injection. 
1.0 0.9 NMT 2.0 
The Theoretical plate count for 
Vitamin E and Ubidecarenone peak 
from first standard injection. 
7839 8664 NLT 2000 
The %RSD for RT of Vitamin E and 
Ubidecarenone peak from 6 replicate 
injections of standard solution. 
0.0 0.0 NMT 1.0 
The %RSD for Peak responses of 
Vitamin E and Ubidecarenone peak 
from 6 replicate injections of standard 
solution. 
0.5 0.2 NMT 2.0 
 
 
Stressed conditions Content in % Vitamin E % Degradation Peak purity index 
Unstressed sample 101.9 NA 1.000 
Acid Hydrolysis (0.1M 
HCl)  reflux for 20 min  at 
60°C 
97.7 4.1 1.000 
 Base Hydrolysis (0.1M 
NaOH) reflux for 20 min  at 
60°C 
97.8 4.0 1.000 
 Oxidation reflux (1%H2O2) 
for 20 min  at 60°C 99.9 1.9 1.000 
 
 
 
Stressed conditions Content in % Vitamin E % Degradation % Degradation 
 Water  Hydrolysis reflux for 
20 min  at 60°C 98.3 3.5 1.000 
Exposed to heat for a period 
of 1 hour at 1050C.  97.7 4.1 1.000 
 Exposed to humidity i.e. 
90% RH and 25°C in a 
desiccator for 7 days. 
98.7 3.1 1.000 
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Stressed conditions Content in % Ubidecarenone % Degradation Peak purity index 
Unstressed sample 109.9 NA 1.000 
Acid Hydrolysis (0.1M 
HCl)  reflux for 20 min  at 
60°C 
103.6 5.7 1.000 
 Base Hydrolysis (0.1M 
NaOH) reflux for 20 min  
at 60°C 
105.6 3.9 1.000 
 Oxidation reflux (1%H2O2) 
for 20 min  at 60°C 107.7 2.0 1.000 
 Water  Hydrolysis reflux 
for 20 min  at 60°C 105.0 4.4 1.000 
Exposed to heat for a 
period of 1 hour at 1050C.  105.3 4.1 1.000 
 Exposed to humidity i.e. 
90% RH and 25°C in a 
desiccator for 7 days. 
106.4 3.1 1.000 
 
Interference: Blank and Placebo does not show any interference at main peak RT. 
 
Conclusion:  
The chromatograms of stressed Blank, Placebo and sample solutions shows that there 
is no interference of Blank and placebo peaks and degradants peaks at the retention 
times of Vitamin E and Ubidecarenone. The peak purity index values of standard and 
sample solutions are within the Acceptance criteria. Hence it is concluded that the 
method is specific to estimate the amount of Vitamin E and Ubidecarenone without 
the interference of Blank, placebo peaks and degradant peaks and the method is 
Stability indicating. 
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12.0 LINEARITY  AND RANGE: 
 
  The linearity of the method is established by performing five test concentrations from 50.0% to 150% of working concentrations as 
per protocol.  The standard solutions were prepared with the concentrations of 50%, 75%, 100%, 125% and 150% with respect to 100% 
working concentration. For each concentration 3 replicate injections are given into HPLC system. Based on the average area obtained 
with each concentration, a graph is plotted between Area and Concentration. The details are given below. 
 
 For Vitamin E and Ubidecarenone: 
 
 
% 
Concentratio
n 
Vitamin 
E  
Solution-
I 
Ubidecareno
ne  
Solution-II 
Volume of 
solution-I and 
solution-II 
taken in mL 
Conc. in  ppm Average Peak area  
Vitamin 
E Ubidecarenone 
Vitamin 
E Ubidecarenone 
50 
125.0 mg  
↓ 
100 mL 
500.1 mg  
↓  
100 mL 
5.0 → 100mL 60.1250  249.0498 150675 3218474 
75 7.5 → 100mL 90.1875 373.5797 234094 4727876 
100 10.0 → 100mL 120.2500 498.0996 312789 6751585 
125 12.5 → 100mL 150.3125 622.6245 389076 8233691 
150 15.0 → 100mL 180.3750 747.1494 470129 9693325 
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Acceptance criteria:  
 
For Vitamin E and Ubidecarenone 
 
System Suitability 
Parameters 
Observed value 
Acceptance 
criteria Vitamin E Ubidecareno
ne 
Correlation coefficient(r) 0.999 0.999  NLT 0.999 
% of y-Intercept 0.0 -0.3  ±2.0 
 
Conclusion: 
The Correlation coefficient and y-Intercept of the plot for Vitamin E and 
Ubidecarenone are well within the acceptance criteria. Hence it is concluded that the 
method is linear within the concentration of 50% to 150% with respect 100 % 
working concentration. 
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13.0 ACCURACY: 
Accuracy is the closeness of the test results obtained by the method with the true 
value. Accuracy may often be expressed as percent recovery by the Assay of known, 
added amounts of analyte. Accuracy is a measure of the exactness of analytical 
method. 
 
 
Accuracy was assessed using ‘3’ concentration (50.0%, 100.0% and 150.0%). 
 
 
As per the protocol Standard and spiked sample solutions are prepared with 
concentrations of 50%, 100%, and 150%. Based on the area obtained for each 
concentration, % of Recovery is calculated. The details are given below 
 
For Vitamin E: 
 
S 
No. 
Concen
tration 
Amount of 
Vitamin E  
added in ppm 
Amount of 
Vitamin E 
recovered in ppm 
Recovery  
in % 
Average 
in % 
RSD 
in 
% 
01 
50.0% 62.5000 62.7428 100.3884 
100.256
9 0.1 50.0% 62.5000 62.6244 100.1990 
50.0% 62.5000 62.6146 100.1833 
02 
100.0% 125.0000 123.2476 98.5980 
99.3569 0.6 100.0% 125.0000 124.6951 99.7560 
100.0% 125.0000 124.6459 99.7167 
03 
150.0% 187.5000 187.0042 99.7355 
100.469
2 0.6 150.0% 187.5000 189.0215 100.8114 
150.0% 187.5000 189.1141 100.8608 
Average 100.0 
NA %RSD 0.6 
 
 
For Ubidecarenone: 
 
S 
No. 
Concen
tration 
Amount of 
Ubidecarenone     
added in ppm 
Amount of 
Ubidecarenone    
recovered in ppm 
Recovery  
in % 
Average 
in % 
RSD 
in % 
01 
50.0% 250.0500 250.3419 100.1167 
100.0251 0.0 50.0% 250.0500 249.9710 99.9684 
50.0% 250.0500 250.0256 99.9902 
02 
100.0% 500.1000 494.7706 98.9343 
99.3286 0.3 100.0% 500.1000 497.4267 99.4654 
100.0% 500.1000 498.0302 99.5861 
03 
150.0% 750.1500 749.6704 99.9360 
100.9339 0.8 150.0% 750.1500 761.0400 101.4517 
150.0% 750.1500 760.7575 101.4140 
Average 100.1 
NA %RSD 0.8 
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Acceptance criteria:   
System suitability parameters 
Observation Acceptanc
e criteria Vitamin E Ubidecareno
ne 
The Tailing factor for Vitamin E and 
Ubidecarenone peak from first standard 
injection. 
1.0 0.9 NMT 2.0 
The Theoretical plate count for Vitamin E 
and Ubidecarenone    peak from first 
standard injection. 
8011 9030 NLT 2000 
 The %RSD for RT of Vitamin E and 
Ubidecarenone peak from 6 replicate 
injections of standard solution. 
0.0 0.0 NMT 1.0 
 The %RSD for Peak responses of 
Vitamin E and Ubidecarenone    peak 
from 6 replicate injections of standard 
solution. 
0.3 0.4 NMT 2.0 
The % system drift between standard and 
bracketing standard 99.5 99.3 
97.5 - 
102.5 
 The average % of recovery from all 
accuracy level concentrations 100.0 100.1 
98.0 to 
102.0 
 The % RSD of Recovery from all 
accuracy level concentrations 0.6 0.8 NMT 2.0 
 
Conclusion: 
The recovery obtained with each concentration level, % RSD of recovery was within 
the acceptance criteria. Hence it is concluded that the method is accurate and precise 
in the range of 50% to 150% with respect to 100% working concentration. 
 
14.0 PRECISION: 
14.1 System Precision 
As per protocol Standard Solution of Vitamin E and Ubidecarenone was prepared and 
injected in six replicates into HPLC System. The system suitability parameters were 
calculated as per protocol and the results are tabulated as shown below. 
 
 
For Vitamin E: 
 
No of Injection RT Response 
01 5.3 297917 
02 5.3 297741 
03 5.3 297764 
04 5.3 297575 
05 5.3 297643 
06 5.3 297660 
Mean 5.3 297717 
SD 0.0 120 
%RSD 0.1 0.0 
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For Ubidecarenone: 
 
No of Injection RT Response 
01 16.9 6641820 
02 16.9 6704813 
03 16.9 6686954 
04 16.9 6687865 
05 16.9 6681671 
06 16.9 6703523 
Mean 16.9 6684441 
SD 0.0 22897 
%RSD 0.0 0.3 
 
Acceptance criteria:  
 
System Suitability Parameters 
Observation Acceptanc
e criteria Vitamin E Ubidecareno
ne 
The Tailing factor for Vitamin E and 
Ubidecarenone peak from first standard 
injection. 
1.0 0.9 NMT 2.0 
The Theoretical plate count for Vitamin E 
and Ubidecarenone peak from first 
standard injection. 
6537 8268 NLT 2000 
 The %RSD for RT of Vitamin E and 
Ubidecarenone peak from 6 replicate 
injections of standard solution. 
0.1 0.0 NMT 1.0 
 The %RSD for Peak responses of Vitamin 
E and Ubidecarenone l peak from 6 
replicate injections of standard solution 
0.0 0.3 NMT 2.0 
 
Conclusion: 
The system suitability parameters are within the acceptance criteria. Hence the system 
is suitable to carry out the analysis for estimation of Content of Vitamin E and 
Ubidecarenone in “Ubidecarenone 50mg and Vitamin E 12.5mg Capsules”. 
 
14.2 Method precision: 
Product Name:  “Ubidecarenone 50mg and Vitamin E 12.5mg Capsules”. 
B.No.: SRT17028 
 
As per protocol 6 replicate Sample Solution of “Ubidecarenone 50mg and Vitamin E 
12.5mg Capsules” were prepared and injected into HPLC System. The Method 
precision parameters are calculated as per protocol and the results are tabulated as 
shown below. 
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For VitaminE and Ubidecarenone: 
 
 
Content % of content of Vitamin E % of content of Ubidecarenone 
HPLC I.D AD/EQP/004 AD/EQP/004 
COLUMN I.D 
NO SHCA018 SHCA018 
Analyst name BHARATHI DASAN BHARATHI DASAN 
Date 07/04/17 07/04/17 
       Preparation 
1 102.0176 109.3712 
2 101.8992 109.8318 
3 101.3784 108.6474 
4 101.8832 109.4470 
5 101.6424 109.4618 
6 101.1080 108.9990 
Average 101.7 109.3 
SD 0.3518 0.4127 
%RSD 0.3 0.3 
Confidence limit 0.2 0.3 
 
Acceptance criteria:  
System Suitability Parameters 
Observation Acceptanc
e criteria Vitamin E Ubidecarenon
e 
The Tailing factor for Vitamin E and 
Ubidecarenone peak from first standard 
injection. 
1.0 0.9 NMT 2.0 
The Theoretical plate count for Vitamin E 
and Ubidecarenone  peak from first 
standard injection. 
6537 8268 NLT 2000 
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System Suitability Parameters 
Observation Acceptance 
criteria Vitamin E Ubidecarenon
e 
 The %RSD for RT of Vitamin E and 
Ubidecarenone peak from 6 replicate 
injections of standard solution. 
0.1 0.0 NMT 1.0 
 The %RSD for Peak responses of Vitamin 
E and Ubidecarenone peak from 6 
replicate injections of standard solution 
0.0 0.3 NMT 2.0 
The % system drift between standard and 
bracketing standard 100.3 101.9 97.5 - 102.5 
 The Average % Content of Vitamin E and 
Ubidecarenone from 6 replicate sample 
preparation 
101.7 109.3 
Vitamin E 
90.0 to 112.2 
Ubidecarenon
e 
90.0 to 121.0 
 The % RSD of % Content of Vitamin E 
and Ubidecarenone from 6 replicate 
sample preparations 
0.3 0.3 NMT 2.0 
 Confidence limit 0.2 0.3 ±5.0 
 
Conclusion: 
The Assay values of 6 replicate preparations and % RSD show that the method is 
precise and repeatable. 
 
14.3 Intermediate Precision (Reproducibility):   
Intermediate precision is demonstrated by analyzing the same batch of “Ubidecarenone 
50mg and Vitamin E 12.5mg Capsules”, as in Method precision with 6 replicate 
samples, in the different lab and a different Analyst, using a different Instrument and 
column on a different day.   
 
For Vitamin E: 
No of Injection RT Response 
01 4.7 317006 
02 4.7 317971 
03 4.7 317507 
04 4.7 317913 
05 4.7 317873 
06 4.8 317905 
Mean 4.7 317696 
SD 0.0 377 
%RSD 0.3 0.1 
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For Ubidecarenone: 
No of Injection RT Response 
01 13.0 7229718 
02 13.0 7250311 
03 13.1 7245759 
04 13.1 7242011 
05 13.1 7222362 
06 13.1 7225613 
Mean 13.1 7235962 
SD 0.0 11571 
%RSD 0.4 0.1 
 
 
For VitaminE and Ubidecarenone: 
 
Content % of content of Vitamin E % of content of Ubidecarenone 
HPLC I.D NO AD/EQP/004 AD/EQP/004 
COLUMN I.D 
NO SHCA018 SHCA018 
Analyst name BHARATHI DASAN BHARATHI DASAN 
Date 07/04/17 07/04/17 
1 101.9 109.1 
2 101.8 109.1 
3 101.8 110 
4 101.7 109 
5 101.9 108 
6 101.6 109.9 
Average 101.8 109.2 
SD 0.116 0.725 
%RSD 0.1 0.6 
Confidence limit 0.0 0.5 
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Vitamin E: 
 
 
Parameter Method precision Intermediate precision 
HPLC I.D No AD/EQP/004 QC/EQP/126 
COLUMN I.D NO SHCA018 SHCA021 
Analyst name BHARATHI DASAN PREETHAM 
Date 07/04/17 09/04/17 
1 102.0176 101.8296 
2 101.8992 101.8200 
3 101.3784 101.7672 
4 101.8832 101.6576 
5 101.6424 101.8656 
6 101.1080 101.5768 
Average 101.7 101.8 
SD 0.3518 0.1125 
%RSD 0.3 0.1 
Confidence limits 0.2 0.0 
 
 
 
 
For Ubidecarenone: 
 
Parameter Method precision Intermediate precision 
HPLC I.D No AD/EQP/004 QC/EQP/126 
COLUMN I.D NO SHCA018 SHCA021 
Analyst name BHARATHI DASAN PREETHAM 
Date 07/04/17 09/04/17 
1 109.3712 109.1072 
2 109.8318 109.0946 
3 108.6474 109.9746 
4 109.4470 108.9732 
5 109.4618 107.9914 
6 108.9990 109.8460 
Average 109.3 109.2 
SD 0.4127 0.7129 
%RSD 0.3 0.6 
Confidence limits 0.3 0.5 
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Summary Results: 
System Suitability Parameters 
Observation 
Acceptance 
criteria Vitamin E Ubidecareno
ne 
The Tailing factor for Vitamin E and 
Ubidecarenone peak from first 
standard injection. 
1.1 1.0 NMT 2.0 
The Theoretical plate count for 
Vitamin E and Ubidecarenone peak 
from first standard injection. 
6691 7914 NLT 2000 
 The %RSD for RT of Vitamin E and 
Ubidecarenone peak from 6 replicate 
injections of standard solution. 
0.3 0.4 NMT 1.0 
 The %RSD for Peak responses of 
Vitamin E and Ubidecarenone peak 
from 6 replicate injections of standard 
solution 
0.1 0.1 NMT 2.0 
The % system drift between standard 
and bracketing standard 
99.8 101.2 97.5 - 102.5 
 The Average % Content of Vitamin E 
and Ubidecarenone from 6 replicate 
sample preparation 
101.8 109.2 
Vitamin E 
90.0 to 112.2 
Ubidecareno
ne 
90.0 to 121.0 
 The % RSD of % Content of Vitamin E 
and Ubidecarenone from 6 replicate 
sample preparations 
0.1 0.6 NMT 2.0 
 The % RSD of % Content of Vitamin E 
and Ubidecarenone obtained for 12 
replicate sample preparations obtained 
from Analyst-1(Method Precision) and 
Analyst-2(Intermediate Precision) 
0.2 0.5 NMT 2.0 
Confidence limits for 12 replicate 
sample preparations 0.1 0.3 ± 5.0 
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Conclusion: 
The Assay values of 6 replicate preparations and % RSD values obtained by Analyst-
1 and Analyst-2 using two different HPLC systems, Column and performed on two 
different day’s shows that the method is precise and reproducible. 
 
 
 
 
15.0 RUGGEDNESS: 
The Ruggedness has been demonstrated by injecting six samples prepared as per the 
test preparation given in the method of analysis on two different days, with two 
different analysts, column and different system (minimum two different systems) of 
the product “Ubidecarenone 50mg and Vitamin E 12.5mg Capsules” bearing batch 
number SRT17028. 
 
15.1  System to System variability 
 
Refer intermediate precision 
 
    15.2 Column to Column variability:  
  
 Refer intermediate precision 
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16.0 ROBUSTNESS: 
The robustness of the analytical method for Content of Vitamin E and Ubidecarenone in “Ubidecarenone 50mg and Vitamin E 12.5mg 
Capsules” is demonstrated with small but deliberate variations in Column Oven Temperature, flow rate and wavelength.  
The robustness of the analytical method is demonstrated by small variations in the flow rate (1.3 mL/min, 1.5 mL/min and 1.7 mL/min) 
as per protocol. The standard and sample solutions were prepared and injected into HPLC as per the method. The results obtained are 
listed below.  
 
System suitability parameters Observed Value Acceptance 
criteria Flow rate (mL/minute) 1.3mL/min 1.5mL/min 1.8mL/min 
a b a b a b 
The Tailing factor for Vitamin E and Ubidecarenone peak from first 
standard injection. 1.0 0.9 1.0 0.9 1.0 0.9 NMT 2.0 
The Theoretical plate count for Vitamin E and Ubidecarenone peak from 
first standard injection. 7172 8843 6537 8268 6007 7894 NLT 2000 
The %RSD for RT of Vitamin E and Ubidecarenone peak from 6 replicate 
injections of standard solution. 0.0 0.0 0.1 0.0 0.2 0.1 NMT 1.0 
The %RSD for Peak responses of Vitamin E and Ubidecarenone peak from 
6 replicate injections of standard solution 0.0 0.3 0.0 0.3 0.3 0.1 NMT 2.0 
The avg %  Content of Vitamin E and Ubidecarenone obtained from two 
replicate preparation of sample at three different flow rate  
101.
5 
107.
0 
102.
0 
109.
7 
101.
5 
106.
9 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The % system drift between standard and bracketing standard 99.9 100.4 
100.
3 
101.
9 
100.
6 
100.
4 97.5 - 102.5 
The average % Content of Vitamin E and Ubidecarenone obtained with 
three different flowrates 
Vitamin E – 101.7 Vitamin E 90.0 to 112.2 
Ubidecarenone – 107.9 Ubidecarenone 90.0 to 121.0 
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16.1 Effect of variation in flow rate (mL/minute): 
Conclusion: 
The results obtained are within the acceptance criteria. Hence it is concluded that the method is Robust with respect to small variations in 
the flow rate. 
16.2 Effect of variation in Column Oven Temperature (ºC): 
 
The average % RSD for avg % Content of Vitamin E and Ubidecarenone 
obtained with three different flowrates 
Vitamin E – 0.2 NMT 2.0 Ubidecarenone – 1.4 
System suitability parameters Observed Value  
Acceptance 
criteria 
Column Oven Temperature (ºC) 38ºC 40ºC 42ºC 
a b a b a b 
The Tailing factor for Vitamin E and Ubidecarenone peak from first standard 
injection. 0.9 0.9 1.0 0.9 0.9 0.9 NMT 2.0 
The Theoretical plate count for Vitamin E and Ubidecarenone peak from first 
standard injection. 
652
4 8278 6537 8268 6568 8454 NLT 2000 
The %RSD for RT of Vitamin E and Ubidecarenone peak from 6 replicate 
injections of standard solution. 0.0 0.0 0.1 0.0 0.0 0.0 NMT 1.0 
The %RSD for Peak responses of Vitamin E and Ubidecarenone peak from 6 
replicate injections of standard solution 0.1 0.1 0.0 0.3 0.1 0.4 NMT 2.0 
The avg %  Content of Vitamin E and Ubidecarenone obtained from two 
replicate preparation of sample at three different flow rate  
101.
5 
107.
1 
102.
0 
109.
7 
101.
6 
107.
1 
Vitamin E 
90.0 to 112.2 
Ubidecarenon
e 
90.0 to 121.0 
The % system drift between standard and bracketing standard 99.4 100.9 
100.
3 
101.
9 99.8 
100.
4 97.5 - 102.5 
The average % Content of Vitamin E and Ubidecarenone obtained with three 
different Column Oven Temperatures 
Vitamin E – 101.7 Vitamin E 90.0 to 112.2 
Ubidecarenone – 108.0 Ubidecarenoe
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Conclusion: 
The results obtained are within the acceptance criteria. Hence it is concluded that the method is Robust with respect to small variations of 
column oven Temperatures. 
16.3Effect of variation in wavelength: 
 
System suitability parameters Observed Value Acceptance 
criteria Wavelength (nm) 273 nm 275nm 277nm 
a b a b a b 
The Tailing factor for Vitamin E and Ubidecarenone peak from first 
standard injection. 1.0 0.9 1.0 0.9 1.0 0.9 NMT 2.0 
The Theoretical plate count for Vitamin E and Ubidecarenone peak from 
first standard injection. 
653
1 8271 6537 8268 6540 8264 NLT 2000 
The %RSD for RT of Vitamin E and Ubidecarenone peak from 6 replicate 
injections of standard solution. 0.1 0.0 0.1 0.0 0.1 0.0 NMT 1.0 
The %RSD for Peak responses of Vitamin E and Ubidecarenone peak from 
6 replicate injections of standard solution 0.0 0.2 0.0 0.3 0.0 0.2 NMT 2.0 
The avg %  Content of Vitamin E and Ubidecarenone obtained from two 
replicate preparation of sample at three different wavelengths 
101.
8 
109.
7 
102.
0 
109.
7 
101.
7 
109.
7 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The % system drift between standard and bracketing standard 100.3 
101.
8 
100.
3 
101.
9 
100.
4 
101.
9 97.5 - 102.5 
The average % Content of Vitamin E and Ubidecarenone obtained with 
three different wavelengths 
Vitamin E – 101.9 Vitamin E 90.0 to 112.2 
Ubidecarenone – 109.7 Ubidecarenone 
90.0 to 121.0 
The average % RSD for avg % Content of Vitamin E and Ubidecarenone 
obtained with three different Column Oven Temperatures 
Vitamin E – 0.2 NMT 2.0 Ubidecarenone – 1.3 
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90.0 to 121.0 
The average % RSD for avg % Content of Vitamin E and Ubidecarenone 
obtained with three different wavelengths 
Vitamin E – 0.1 NMT 2.0 Ubidecarenone – 0.0  
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Conclusion: 
The results obtained are within the acceptance criteria. Hence it is concluded that the 
method is Robust with respect to small variations in wavelength. 
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17.0 FILTER VALIDATION:  
Filter validation was demonstrated by assaying the sample without filtration by centrifuging the sample solution, filtering through 0.45 µm nylon 
and through Whatman filter no.42 
 
Results are summarised in the table below: 
 
Acceptance criteria:  
System Suitability Parameters Observation Acceptance criteria Vitamin E Ubidecarenone 
The Tailing factor for Vitamin E and Ubidecarenone peak 
from first standard injection. 1.0 0.9 NMT 2.0 
The Theoretical plate count for Vitamin E and 
Ubidecarenone    peak from first standard injection. 6537 8268 NLT 2000 
 The %RSD for RT of Vitamin E and Ubidecarenone peak 
from 6 replicate injections of standard solution. 0.1 0.0 NMT 1.0 
 The %RSD for Peak responses of Vitamin E and 
Ubidecarenone peak from 6 replicate injections of standard 
solution. 
0.0 0.3 NMT 2.0 
The % system drift between standard and bracketing 
standard 99.8 100.0 97.5 - 102.5 
 The avg % Content of Vitamin E from 2 replicate sample 
preparations. 
Whatman 42.0 0.45µ nylon Centrifuged 90.0 to 112.2 101.6 101.6 101.2 
 The avg % Content of Ubidecarenone from 2 replicate 
sample preparations. 
Whatman 42.0 0.45µ nylon Centrifuged 90.0 to 121.0 108.9 108.6 108.3 
 The % RSD for Content of Vitamin E and Ubidecarenone   
from Three different Filters.  0.2 0.2 NMT 2.0 
. 
Conclusion: The results obtained with different filter paper shows that both filter papers are suitable for filtration. 
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18.0 STABILITY OF ANALYTICAL SOLUTIONS 
 
The solution stability is demonstrated by injecting standard and sample solution up to 48 hours.  The % RSD of area of standard and sample 
solutions are calculated as shown below 
 
 
Time Intervals Standard Area Sample Area 
Vitamin E Ubidecarenone Vitamin E Ubidecarenone 
Initial 297526 6708024 367659 8153091 
12th Hour 299465 6707194 365803 8072624 
24th Hour 299476 6664461 365480 8037270 
36th Hour 296708 6612099 368069 8035820 
48th Hour 297697 6506242 367263 8020547 
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Average 298174 6639604 366855 8063870 
Std dev 1241 84275 1149 53405 
% RSD 0.4 1.2 0.3 0.6 
 
Acceptance criteria:   
System Suitability Parameters 
Observation Acceptanc
e criteria Vitamin E Ubidecaren
one 
The Tailing factor for Vitamin E and 
Ubidecarenone peak from first standard 
injection. 
1.0 0.9 NMT 2.0 
The Theoretical plate count for Vitamin E 
and Ubidecarenone peak from first 
standard injection. 
6505 8253 NLT 2000 
 The % RSD of the peak area of Vitamin E 
and Ubidecarenone for solution to be 
stable for standard. 
0.4 1.2 NMT 2.0 
 The % RSD of the peak area of Vitamin E 
and Ubidecarenone for solution to be 
stable for sample. 
0.3 0.6 NMT 2.0 
 
 
 
Conclusion:  
The % RSD of area of Standard and sample solution obtained with different time 
interval shows that both standard and sample solutions are stable up to 48 hours at 
room temperature. 
 
 
 
 
18.0 SUMMARY AND CONCLUSION: 
 
Parameter          Experiment Observed value Acceptance criteria 
a b 
System 
precision 
The Tailing factor for Vitamin E and 
Ubidecarenone peak from first standard 
injection. 
1.0 0.9 NMT 2.0 
The Theoretical plate count for Vitamin 
E and Ubidecarenone peak from first 
standard injection. 
6537 8268 NLT 2000 
The %RSD for RT of Vitamin E and 
Ubidecarenone peak from 6 replicate 
injections of standard solution. 
0.1 0.0 NMT 1.0 
The  % RSD for the peak area response 
of Vitamin E and Ubidecarenone    from 
standard preparations 
0.0 0.3 NMT 2.0 
Specificity Placebo and Blank Solution interference 
The Placebo and 
Blank solution 
do not show any 
peak at the 
The Placebo and 
Blank solution should 
not show any peak at 
the retention time of 
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Parameter          Experiment Observed value Acceptance criteria 
a b 
retention time of 
Ubidecarenone  
and Vitamin E  
Ubidecarenone  and 
Vitamin E 
Vitamin E and Ubidecarenone    
Standard (Peak purity index) 
a b The Peak Purity index 
of standard and 
sample  should not be 
less than 0.99 
0.999 0.999 
Vitamin E and Ubidecarenone    Sample 
(Peak purity index) 1.000 1.000 
Forced 
degradatio
n study 
Acid Hydrolysis  1.000 1.000 
The Peak Purity index 
of sample  should not 
be less than 0.99 
Base Hydrolysis  1.000 1.000 
Water  Hydrolysis  1.000 1.000 
Oxidation  1.000 1.000 
Exposed to humidity of Sample 1.000 1.000 
Exposed to humidity of Sample  1.000 1.000 
Linearity 
and Range 
Correlation Coefficient( r) for Vitamin E 
and Ubidecarenone  0.999 0.999 NLT 0.999 
The % of y-Intercept  0.0. -0.3 ± 2.0 
Accuracy 
The average % Recovery for Vitamin E 
and Ubidecarenone  from all levels 100.0 100.1 98.0 to 102.0 
The  % RSD of recovery in all 
concentrations  0.6 0.8 NMT 2.0 
The % system drift between standard 
and bracketing standard 99.5 99.3 97.5-102.5 
Precision 
System Precision 
The Tailing factor for Vitamin E and 
Ubidecarenone peak from first standard 
injection. 
1.0 0.9 NMT 2.0 
The Theoretical plate count for Vitamin 
E and Ubidecarenone peak from first 
standard injection. 
6537 8268 NLT 2000 
The %RSD for RT of Vitamin E and 
Ubidecarenone peak from 6 replicate 
injections of standard solution. 
0.1 0.0 NMT 1.0 
The  % RSD for the peak area response 
of Vitamin E and Ubidecarenone from 
standard preparations 
0.0 0.3 NMT 2.0 
Method Precision (system-1) 
The Average % Content of Vitamin E 
and Ubidecarenone obtained from 6 
replicate sample preparations 
101.7 109.3 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The  % RSD of % Content of  Vitamin 
E and Ubidecarenone obtained from 6 
replicate sample preparations 
0.3 0.3 NMT 2.0 
Confidence limits of  Ubidecarenone  
and Vitamin E 0.2 0.3 ±5.0 
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Parameter          Experiment Observed value Acceptance criteria 
a b 
The % system drift between standard 
and bracketing standard 100.3 101.9 97.5-102.5 
Intermediate Precision (Reproducibility) (system-2) 
The Tailing factor for Vitamin E and 
Ubidecarenone peak from first standard 
injection. 
1.1 1.0 NMT 2.0 
The Theoretical plate count for Vitamin 
E and Ubidecarenone    peak from first 
standard injection. 
6691 7914 NLT 2000 
The %RSD for RT of Vitamin E and 
Ubidecarenone    peak from 6 replicate 
injections of standard solution. 
0.3 0.4 NMT 1.0 
The  % RSD for the peak area response 
of Vitamin E and Ubidecarenone    from 
standard preparations 
0.1 0.1 NMT 2.0 
The  Average % Content of Vitamin E 
and Ubidecarenone    obtained from 6 
replicate sample preparations 
101.8 109.2 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
Confidence limits  0.0 0.5 ± 5.0 
The  % RSD of % Content of Vitamin E 
and Ubidecarenone    obtained from 6 
replicate sample preparations 
0.1 0.6 
NMT 2.0 The  % RSD of % Content of Vitamin E 
and Ubidecarenone    obtained from 12 
replicate sample preparations Analyst-1 
(Method Precision) & Analyst-2 
(Intermediate Precision) 
0.2 0.5 
The % system drift between standard 
and bracketing standard 99.8 101.2 97.5-102.5 
Ruggedness 
System to System Variability 
The  Average % Content of Vitamin E 
and Ubidecarenone    obtained from 6 
replicate sample preparations (system-1) 
101.7 109.3 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The  Average % Content of Vitamin E 
and Ubidecarenone    obtained from 6 
replicate sample preparations (system-2) 
101.8 109.2 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The % RSD of % Content of Vitamin E 
and Ubidecarenone    obtained from 6 
replicate sample preparations (system-1) 
0.3 0.3 NMT 2.0 
The % RSD of % Content of Vitamin E 
and Ubidecarenone    obtained from 6 
replicate sample preparations (system-2) 
0.1 0.6 NMT 2.0 
Column to Column Variability 
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Parameter          Experiment Observed value Acceptance criteria 
a b 
The Average % of Content of Vitamin E 
and Ubidecarenone obtained from 6 
replicate sample preparations (system-1) 
101.7 109.3 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The Average % of Content of Vitamin E 
and Ubidecarenone obtained from 6 
replicate sample preparations (system-2) 
101.8 109.2 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The % RSD of mg Content of Vitamin E 
and Ubidecarenone    obtained from 6 
replicate sample preparations (Column -
1) 
0.3 0.3 NMT 2.0 
The % RSD of mg Content of Vitamin E 
and Ubidecarenone    obtained from 6 
replicate sample preparations (Column -
2) 
0.1 0.6 NMT 2.0 
Robustness 
Variation in Flow rate 
The  average % content of Vitamin E 
and Ubidecarenone    obtained at three 
different flow rate 
1) 1.3 mL/min 
2) 1.5 mL/min 
      3)   1.7 mL/min 
101.5 
102.0 
101.5 
107.0 
109.7 
106.9 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The  % RSD of % Content of Vitamin E 
and Ubidecarenone    obtained at three 
different flow rates 
0.2 1.4 NMT 2.0 
The % system drift between standard 
and bracketing standard 
1) 1.3 mL/min 
2) 1.5 mL/min 
      3)   1.7 mL/min 
99.9 
100.3 
100.6 
100.4 
101.9 
100.4 
 
 
97.5-102.5 
Variation in Column Oven Temperature 
The average  % content of Vitamin E 
and Ubidecarenone    obtained at three 
different Temperatures 
1) 380C 
2) 400C 
3) 420C 
101.5 
102.0 
101.6 
107.1 
109.7 
107.1 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The  % RSD of % Content of Vitamin E 
and Ubidecarenone    obtained at three 
different Temperatures 
0.2 1.3 NMT 2.0 
The % system drift between standard 
and bracketing standard 
1) 380C 
2) 400C 
3) 420C 
99.4 
100.3 
99.8 
100.9 
101.9 
100.4 
97.5-102.5 
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Parameter          Experiment Observed value Acceptance criteria 
a b 
 
Variation in Wavelength 
The average % content of Vitamin E and 
Ubidecarenone    obtained at three 
different wavelength 
1) 273 nm 
2) 275 nm 
3) 277 nm 
 
 
101.8 
102.0 
101.7 
 
 
109.7 
109.7 
109.7 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The % RSD of % Content of Vitamin E 
and Ubidecarenone    obtained at three 
different wavelength 
0.1 0.0 NMT 2.0 
The % system drift between standard 
and bracketing standard 
1) 273 nm 
2) 275 nm 
      3)   277 nm 
100.3 
100.3 
100.4 
101.8 
101.9 
101.9 
97.5-102.5 
Filter 
Validation 
The average % content of Vitamin E and 
Ubidecarenone    obtained when 
1) Centrifuged 
2) Filtered with 0.45 µm nylon 
3) Whatman no.42 filter 
 
101.2 
101.6 
101.6 
 
108.3 
108.6 
108.9 
Vitamin E 
90.0 to 112.2 
Ubidecarenone 
90.0 to 121.0 
The % RSD for Content of Vitamin E 
and Ubidecarenone  when centrifuged, 
filtered through whatman no. 42 and  
Nylon 0.45 µm 
0.2 0.2 NMT 2.0 
The % system drift between standard 
and bracketing standard 99.8 100.0 97.5-102.5 
Stability of 
analytical 
solutions 
 
The % RSD for peak areas of Vitamin E 
and Ubidecarenone    from standard 
solution at different time intervals 
0.4 1.2 
NMT 2.0 The % RSD for peak areas of Vitamin E 
and Ubidecarenone    from sample 
solution at different time intervals 
0.3 0.6 
 
a- Vitamin E 
b- Ubidecarenone 
 
 
Conclusion:  
 
The results obtained during Analytical method validation as per protocol number 
AMVP/AD/17/006-00 shows that the assay method for the estimation of Content of 
Vitamin E and Ubidecarenone in “Ubidecarenone 50mg and Vitamin E 12.5mg 
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Capsules” by HPLC method is suitable, linear, precise, accurate, specific, robust and 
rugged. Hence this method can be considered validated and can be used for regular 
analysis.  
 
20.0 Abbreviations used 
NMT : Not more than 
NLT    : Not less than 
RSD  :   Relative standard deviation 
HPLC : High performance liquid chromatography 
UV       : Ultraviolet-Visible 
AMV   :   Analytical method validation 
RT       :   Retention Time 
USP      :   United State Pharmacopoeia 
ICH     :   International Council on Harmonization 
nm        :   Nanometer 
µl         :   Microliter 
mL        :   Milliliter 
mg       : Milligram 
°C     : Degree Celsius 
g         : Gram 
RS      : Reference Standard 
WS      : Working Standard 
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CHROMATOGRAMS 
ANNEXURE-1 
SYSTEM SUITABILITY 
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Blank: 
 
 
Standard: 
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ANNEXURE-2 
SPECIFICITY 
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Specificity Blank:  
 
Specificity Placebo: 
 
 
Specificity Standard: 
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Specificity Sample: 
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Forced Degradation Acid sample 
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Forced Degradation Base sample 
 
 
 
 
 
Forced Degradation Oxidation sample 
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Forced Degradation Hydrolysis sample 
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Forced Degradation Heat sample 
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Forced Degradation Humidity sample 
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ANNEXURE-3 
LINEARITY 
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50% Linearity: 
 
 
75% Linearity 
 
 
100% Linearity: 
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125% Linearity 
 
 
150% Linearity: 
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Linearity curve: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = 3127.x - 286.9 
R² = 0.999 
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ANNEXURE-4 
ACCURACY 
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Accuracy: Blank 
 
50% Accuracy: 
 
100% Accuracy: 
 
 
150% Accuracy: 
 
 
 
 
.                                                                                                                                              Discussion                                          
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 DISCUSSION 
RP-HPLC method 
A Reverse Phase High pressure liquid chromatographic method has been developed for 
simultaneous estimation of Vitamin E and Ubidecarenone in its Softgelatin Capsule form.  
A Waters C18 octadecyl silane (ODS) column (250mmx4.6 mm i.d., 5 mcm Particle size) 
in isocratic mode, with mobile phase Methanol: Ethanol in 50:50 ratio.  The flow rate 
was 1.5 mL per minute and effluent was monitored at 275mm.  The approximate 
retention time for of Vitamin E and Ubidecarenone were 5.3 min and 16.9 min 
respectively.  The linearity for Paracetamol, Aceclofenac and Tramadol was in the range 
of 50% to 150% respectively.  Quantity found for Vitamin E and Ubidecarenone was 
12.7068 mg/av.wt, and 54.6465 mg/av.wt. respectively.  Percentage recoveries obtained 
for the drugs were 101.7% and109.3% respectively.  The proposed method is precise and 
rapid for simultaneous estimation of Vitamin E and Ubidecarenone in Softgelatin 
Capsule formulation. 
Interference studies 
The other active ingredients and common excipients present in the dosage forms of 
Vitamin E and Ubidecarenone did not interfere, when added in the mentioned 
concentration ranges to the drug and estimated by the proposed methods. The methods 
reported here are found to be simple, sensitive.accurate, precise and economical and can 
be used in the determination of Vitamin E and Ubidecarenone from pharmaceutical 
formulations in a routine manner. 
 
                                                                                                                          
                                Summary                              
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SUMMARY 
 
Vitamins and Dietery supplements were very essential to maintain the health of a human 
body.  
Vitamin E has many biological functions. The antioxidant function is considered to be the 
most important function of vitamin E and is the one it is best known for. As it is fat-
soluble, it is incorporated into cell membranes, which protects them from oxidative 
damage. However, there are other functions that have also been recognized to be of 
importance. 
The antioxidant nature of CoQ10 derives from its energy carrier function. As an energy 
carrier, the CoQ10 molecule continuously goes through an oxidation–reduction cycle. As 
it accepts electrons, it becomes reduced. As it gives up electrons, it becomes oxidized. In 
its reduced form, the CoQ10 molecule holds electrons rather loosely, so this CoQ molecule 
will give up one or both electrons quite easily and, thus, act as an antioxidant. CoQ10 
inhibits lipid peroxidation by preventing the production of lipid peroxyl radicals (LOO). 
 
This research work has been taken up to develop and validate simple, sensitive and cost 
effective methods for the estimation of Vitamin E and Ubidecarenone in a combined 
dosage form. 
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